



Check for updates

## NIST Cybersecurity White Paper NIST CSWP 35 ipd

# Cybersecurity Threat Modeling the Genomic Data Sequencing Workflow

*An example threat model implementation for genomic data sequencing and analysis*

Ronald Pulivarti  
*National Cybersecurity Center of Excellence  
National Institute of Standards and  
Technology*

Scott Ross  
Philip Whitlow  
*HudsonAlpha Institute for Biotechnology*

Justin Wagner  
Justin Zook  
*Material Measurement Laboratory  
National Institute of Standards and  
Technology*

Einaam Alim  
Isabelle Brown  
Patrick Pape  
Jared Sheldon  
*The University of Alabama in Huntsville*

Brett Kreider  
Julie Snyder  
Kevin E. Wilson  
Martin Wojtyniak  
*The MITRE Corporation*

This publication is available free of charge from:  
<https://doi.org/10.6028/NIST.CSWP.35.ipd>

December 16, 2024

1 Certain equipment, instruments, software, or materials, commercial or non-commercial, are identified in this  
2 paper in order to specify the experimental procedure adequately. Such identification does not imply  
3 recommendation or endorsement of any product or service by NIST, nor does it imply that the materials or  
4 equipment identified are necessarily the best available for the purpose.

#### 5 **NIST Technical Series Policies**

6 [Copyright, Use, and Licensing Statements](#)

7 [NIST Technical Series Publication Identifier Syntax](#)

#### 8 **How to Cite this NIST Technical Series Publication:**

9 Pulivarti R, Wagner J, Zook, J, Kreider B, Wilson K, Snyder J, Wojtyniak M, Ross S, Whitlow P, Sheldon J, Brown I,  
10 Pape P, Alim E (2024) Cybersecurity Threat Modeling the Genomic Data Sequencing Workflow: An example threat  
11 model implementation for genomic data sequencing and analysis. (National Institute of Standards and Technology,  
12 Gaithersburg, MD), NIST Cybersecurity White Paper (CSWP) NIST CSWP 35 ipd.  
13 <https://doi.org/10.6028/NIST.CSWP.35.ipd>

#### 14 **Author ORCID iDs**

15 Ronald Pulivarti: 0000-0002-8330-3474

16 Justin Wagner: 0009-0003-8903-0504

17 Justin Zook: 0000-0003-2309-8402

18 Brett Kreider: 0009-0004-1508-5876

19 Julie Snyder: 0009-0004-6352-2831

20 Kevin Wilson: 0009-0008-3673-6040

21 Martin Wojtyniak: 0009-0005-9643-2194

22 Mohammad Einaam Alim: 0009-0005-3370-907X

23 Isabelle Brown-Cantrell: 0009-0004-8820-6448

24 Dr. Patrick Pape: 0009-0005-4922-4026

25 Scott Ross: 0009-0002-8672-6496

26 Jared Sheldon: 0009-0009-7909-4217

27 Philip Whitlow: 0009-0000-7677-3825

#### 28 **Public Comment Period**

29 December 16, 2024 – January 30, 2024

30 All comments are subject to release under the Freedom of Information Act.

#### 31 **Submit Comments**

32 Please submit comments to [genomic\\_cybersecurity\\_nccoe@nist.gov](mailto:genomic_cybersecurity_nccoe@nist.gov) with "Comments on NIST CSWP 35" in the  
33 subject field. We encourage you to [use this comment template](#).

34

35 National Institute of Standards and Technology

36 Attn: Applied Cybersecurity Division, Information Technology Laboratory

37 100 Bureau Drive (Mail Stop 2000) Gaithersburg, MD 20899-2000

#### 38 **Additional Information**

39 Additional information about this publication is available at <CSRC link>, including related content, potential  
40 updates, and document history.

41 **All comments are subject to release under the Freedom of Information Act (FOIA).**

42

43 **Abstract**

44 Advancements in genomic sequencing technologies are accelerating the speed and volume of  
45 data collection, sequencing, and analysis. However, this progress also heightens cybersecurity  
46 and privacy risks. In this paper, the National Cybersecurity Center of Excellence (NCCoE)  
47 Genomic Data project team demonstrates a cybersecurity threat modeling using an example  
48 workflow involving an organization sending a physical sample to a genomic sequencing  
49 provider, then receiving back and processing the genomic data. This paper provides an example  
50 of how to conduct cybersecurity threat modeling, including documenting the architecture,  
51 identifying threats, applying sample mitigations, and iterating the process as needed. While this  
52 paper focuses on cybersecurity threats, future work will demonstrate how to conduct a similar  
53 analysis for privacy.

54 **Keywords**

55 *Cybersecurity Framework Profile; DNA sequencing; genomics; genomic data; genomic*  
56 *sequencing; human genome; threat modeling; threat mitigations.*

57 **Feedback**

58 NIST welcomes feedback and input on any aspect of NIST CSWP 35 and additionally proposes a  
59 list of non-exhaustive questions and topics for consideration:

- 60 1. How well do the threat modeling practices in this white paper relate to existing threat  
61 modeling practices leveraged by your organization? Are there significant gaps between  
62 the sets of practices that this paper should address?
- 63 2. How do you expect this white paper to influence your future practices and processes?
- 64 3. How do you envision using this white paper? What changes would you like to see to  
65 increase/improve that use?
- 66 4. What suggestions do you have on changing the format of the information provided?  
67 Would it help to provide a more concise overview document with additional detail  
68 provided in either appendices or as part of a more interactive website (e.g., GitHub  
69 Pages as used in the [NCCoE Zero Trust project](#))?
- 70 5. Is the example provided here sufficient for your organization to identify and address  
71 cybersecurity threats in genomic data sequencing or genomic data analysis? Are there  
72 changes or additional content that the authors should consider?

73	<b>Table of Contents</b>	
74	<b>Executive Summary</b> .....	<b>5</b>
75	<b>1. Introduction</b> .....	<b>7</b>
76	1.1. Use Case and Scope .....	7
77	1.2. Organizational Tailoring .....	8
78	1.3. Threats and Risks .....	9
79	1.4. Threat Modeling Overview.....	9
80	1.5. Audience .....	10
81	<b>2. Threat Modeling Example</b> .....	<b>11</b>
82	2.1. Question 1: What are we working on?.....	11
83	2.1.1. Genomics Sequencing Laboratory Data Flow Diagrams .....	13
84	2.1.2. Research Partner Data Flow Diagrams .....	18
85	2.1.3. High-Value Dataflows Overview .....	20
86	2.1.4. Genomic Sequencing Laboratory HVD Examples.....	21
87	2.1.5. Research Partner HVDs.....	24
88	2.2. Question 2: What could go wrong?.....	27
89	2.2.1. Spoofing, Tampering, Repudiation, Information Disclosure, and Elevation of Privilege (STRIDE)	
90	27	
91	2.2.2. Key STRIDE Results .....	29
92	2.2.3. Attack Trees.....	31
93	2.3. Question 3: What are we going to do about it? .....	38
94	2.3.1. Broker Access to Genomic Data.....	41
95	2.3.2. Use Network Isolation and Firewalls .....	41
96	2.3.3. Use RBAC on the Cluster Filesystem .....	45
97	2.3.4. Authenticate and Authorize All Users.....	46
98	2.3.5. Restrict Physical Access to Environments.....	46
99	2.3.6. Implement Data Retention Policies for the Genomic Data.....	46
100	2.3.7. Conduct Backups of Datastores .....	47
101	2.3.8. Containerize Untrusted Software .....	48
102	2.3.9. Implement Least Functionality and use Configuration Benchmarks.....	48
103	2.3.10. Encrypt Data Whenever Possible.....	49
104	2.4. Question 4: Did we do a good job? .....	49
105	2.4.1. Did we do a good job documenting the system and data architecture? .....	50
106	2.4.2. Did we do a good job identifying and documenting threats? .....	51
107	2.4.3. Did we do a good job mitigating the threats? .....	52

108	<b>3. Conclusion</b> .....	<b>55</b>
109	<b>References</b> .....	<b>57</b>
110	<b>Appendix A. Abbreviations and Acronyms</b> .....	<b>59</b>
111	<b>List of Tables</b>	
112	<b>Table 1. Genomic Sequencing Workflow Mission Objectives</b> .....	<b>8</b>
113	<b>Table 2. Symbols Used in Detailed DFDs</b> .....	<b>12</b>
114	<b>Table 3. STRIDE Mnemonic with Examples</b> .....	<b>28</b>
115	<b>Table 4. STRIDE Threats Specific to Genomic Sequencers</b> .....	<b>29</b>
116	<b>Table 5. STRIDE Threats to the Genomic Sequencing Laboratory or Research Partner Environments</b> ..	<b>30</b>
117	<b>Table 6. Details for the Attack Tree 1</b> .....	<b>34</b>
118	<b>Table 7. Details for Attack Tree 2</b> .....	<b>37</b>
119	<b>Table 8. Example Mitigation Table</b> .....	<b>39</b>
120	<b>Table 9. Illumina ACLs</b> .....	<b>43</b>
121	<b>Table 10. PacBio Sequencer ACLs</b> .....	<b>44</b>
122	<b>Table 11. Genomic Sequencing Backup Options</b> .....	<b>47</b>
123	<b>Table 12. STRIDE per Element</b> .....	<b>52</b>
124	<b>List of Figures</b>	
125	<b>Figure 1. Genomic Sequencing Workflow</b> .....	<b>8</b>
126	<b>Figure 2. Visualization of the Four Question Framework for Threat Modeling</b> .....	<b>11</b>
127	<b>Figure 3. High-Level Architecture of the Genomics Sequencing Laboratory</b> .....	<b>14</b>
128	<b>Figure 4. Wet Lab DFD</b> .....	<b>15</b>
129	<b>Figure 5. Sequencer DFD</b> .....	<b>16</b>
130	<b>Figure 6. Data Transfer DFD</b> .....	<b>17</b>
131	<b>Figure 7. Management and Tooling DFD</b> .....	<b>18</b>
132	<b>Figure 8. High Level DFD for Research Partner</b> .....	<b>18</b>
133	<b>Figure 9. Detailed DFD of Research Partner</b> .....	<b>19</b>
134	<b>Figure 10. HVD 1: Cluster Filesystem to Data Delivery DMZ</b> .....	<b>22</b>
135	<b>Figure 11. HVD 2: Sequencer Remote Interface to Manufacturer</b> .....	<b>23</b>
136	<b>Figure 12. HVD 3: Sequencer to Cluster File System</b> .....	<b>23</b>
137	<b>Figure 13. HVD 4: Example of a Method of Running Untrusted Software on Genomic Data</b> .....	<b>25</b>
138	<b>Figure 14. HVD 5: Backing up Sequencing Data to Cloud Storage</b> .....	<b>26</b>
139	<b>Figure 15. HVD 6: Obtaining Genomic Data from Genomic Sequencing Laboratory</b> .....	<b>26</b>
140	<b>Figure 16. Portion of the STRIDE Table Demonstrating Format</b> .....	<b>29</b>

141	<b>Figure 17. Attack Tree 1: Untrusted Software Implanted with Malware .....</b>	<b>33</b>
142	<b>Figure 18. Attack Tree 2: Using the Genomic Sequencer Remote Access to Deploy Ransomware in the</b>	
143	<b>Genomic Sequencing Laboratory Datastore .....</b>	<b>36</b>
144	<b>Figure 19. Certificate Example .....</b>	<b>45</b>
145	<b>Figure 20. Client Certificate Permission List of a Cluster Filesystem.....</b>	<b>49</b>

## 146 Executive Summary

147 In this paper, the National Cybersecurity Center of Excellence (NCCoE) Genomic Data project  
148 team demonstrates how to conduct cybersecurity threat modeling against the environments  
149 involved in genomic sequencing and analysis. The paper demonstrates a common four-step  
150 threat modeling process that can be used as an example for organizations involved in genomic  
151 research, sequencing, and analysis planning to conduct similar threat modeling and identify  
152 mitigations:

- 153 1. Document **“What are we working on?”** through architecture, dataflow, and high-value  
154 dataflow diagrams for the genomic data processing environment ([Sec. 2.1](#)).
- 155 2. Evaluate **“What could go wrong?”** by identifying threats in the environment using tools  
156 such as [STRIDE](#), [MITRE ATT&CK®](#), and attack trees ([Sec. 2.2](#)).
- 157 3. Determine **“What are we going to do about it?”** by prioritizing the identified threats to  
158 help sequence and select initial targets for mitigations, leveraging best practice guides  
159 and existing resources ([Sec. 2.3](#)).
- 160 4. Consider **“Did we do a good job?”** by reviewing the results of the threat modeling  
161 exercise and identifying any additional activities, including high-priority areas where  
162 additional mitigations are needed ([Sec. 2.4](#)).

163 **Background.** Legislation such as the Genetic Information Nondiscrimination Act of 2008 (GINA)  
164 [\[1\]](#) identifies the need to protect genetic data, while Executive Order 14018 [\[2\]](#) lays out the  
165 need to identify risks and develop a protection plan for biological datasets, including genomic  
166 data. Cyber attacks may impact the confidentiality, integrity, and availability of systems that  
167 process genomic data<sup>1</sup>, introducing economic, privacy, discrimination, and national security  
168 risks. Organizations rely on genomic data sharing and aggregation to advance scientific and  
169 medical research, improve health outcomes, and compete within the global bioeconomy.  
170 Cybersecurity and privacy for genomic data are complicated by the nature of the data, which is  
171 immutable and includes kinship, health, and phenotype, as well as the broad, diverse, and  
172 international composition of the genomics community, which includes government, academia,  
173 and industry stakeholders engaged in biopharmaceutical research, healthcare, law  
174 enforcement, agriculture, and direct-to-consumer genetic testing.

175 The paper is part of a larger effort at the NCCoE to engage genomic data processing  
176 stakeholders to create practical guidance that addresses related cybersecurity and privacy  
177 concerns. The [NCCoE Genomic Data website](#) provides links to previous workshops and  
178 publications, including National Institute of Standards and Technology (NIST) Internal Report  
179 (IR) 8432, *Cybersecurity of Genomic Data* [\[3\]](#), and IR 8467, *Genomic Data Cybersecurity and*  
180 *Privacy Frameworks Community Profile (Genomic Data Profile)* [\[4\]](#). Additionally, the NCCoE is

---

<sup>1</sup> Data processing refers to “the complex and interconnected relationships among entities involved in creating or deploying systems, products, or services or any components that process data.” NIST Privacy Framework 1.0  
<https://nvlpubs.nist.gov/nistpubs/CSWP/NIST.CSWP.01162020.pdf>



181 currently developing a privacy-focused guide to address privacy-related concerns, threats, and  
182 risks that will also be published.<sup>2</sup>

---

<sup>2</sup> While cybersecurity threat modeling can support some privacy needs, additional privacy threat modeling efforts are necessary to address the full scope of privacy. For more information regarding the relationship between cybersecurity and privacy risk management, see the *Genomic Data Profile* [\[4\]](#).

## 183 1. Introduction

184 This document provides an example of how to conduct cybersecurity threat modeling on  
185 genomic data processing environments to help identify potential cybersecurity threats, their  
186 impacts, and potential mitigations. The environments represent a basic implementation with  
187 devices, processes, and tools commonly used by government, academia, and industry for  
188 processing genomic data.


189 ***Organizations processing genomic data can use the threat modeling techniques and results  
from this paper to manage cybersecurity threats and reduce cybersecurity risk.***

### 190 1.1. Use Case and Scope

191 This threat modeling example addresses the common use case of sequencing deoxyribonucleic  
192 acid (DNA) and analyzing the results. The bioeconomy<sup>3</sup> relies on this use case for many of its  
193 products and services. The requesting organization (***Research Partner***) sends a physical “wet  
194 lab” DNA sample and associated metadata (in digital form) to a ***Genomic Sequencing  
195 Laboratory*** that processes the sample and returns the digital results in the form of a genomic  
196 sequence. The genomic sequence serves as an input to the Research Partner’s data analysis  
197 pipelines. Genomics as a scientific field has progressed quickly through open sharing of publicly  
198 distributed software. The community benefits greatly by freely sharing this software but should  
199 also consistently implement appropriate risk management practices whenever using this  
200 software in genomic data analysis pipelines. In this paper, we refer to this untrusted, off-the-  
201 shelf, custom, or open-source software (OSS) as “untrusted software.” Figure 1 illustrates this  
202 use case.

---

<sup>3</sup> The economic activity derived from biotechnology and biomanufacturing is referred to as the bioeconomy [2].



203 **Figure 1. Genomic Sequencing Workflow**

204 **1.2. Organizational Tailoring**

205 Organizations that process genomic data need to protect that data due to both its high value  
 206 and the privacy risk to individuals if human genomic data are exposed. Organizations need a  
 207 process to guide the selection of appropriate cybersecurity capabilities to reduce risk to an  
 208 acceptable level for the confidentiality, integrity, and availability of genomic data. Each  
 209 organization should consider its own goals and priorities when tailoring this example to select  
 210 and implement appropriate and cost-effective cybersecurity capabilities to achieve  
 211 organizational outcomes. The organization should also periodically assess its cybersecurity  
 212 posture, considering new technologies and threats to identify gaps in cybersecurity outcomes  
 213 and prioritize mitigations.

214 NIST IR 8467, the *Genomic Data Profile*, provides a prioritized list of Mission Objectives for  
 215 organizations processing genomic data and prioritizes CSF 2.0 Subcategories (or outcomes) to  
 216 support achieving those Mission Objectives. Based on the use case of sequencing genomic  
 217 material, the project team selected three relevant Mission Objectives from the *Genomic Data*  
 218 *Profile* [4], shown in Table 1.

219 **Table 1. Genomic Sequencing Workflow Mission Objectives**

Mission Objectives from the Genomic Data Profile	Mission Objective Description (Keyword)
1	Manage provenance and data quality throughout the genomic data lifecycle ( <b>Data</b> )
3	Identify, model, and address cybersecurity and privacy risks of processing genomic data ( <b>Risks</b> )
8	Facilitate research and education to advance science and technology ( <b>Research</b> )

220 Throughout the paper, CSF 2.0 Subcategories that were prioritized for one or more of the  
221 Mission Objectives in the *Genomic Data Profile* are listed in parentheses and abbreviated as  
222 (CSF Subcategory; Mission Objective). For example, the CSF Subcategory GV.OC-01: “The  
223 organizational mission is understood and informs cybersecurity risk management” comes from  
224 the Govern (GV) Function and the Organizational Context (OC) Category. It received priority  
225 designation for Mission Objective 8 and would be abbreviated as (GV.OC-01; MO:8).

### 226 1.3. Threats and Risks

227 In the bioeconomy, organizations will have differing Mission Objectives and, therefore,  
228 different risks despite facing similar cybersecurity threats. The same threat may have a  
229 different impact or likelihood in two different organizations or use cases. For example, a denial-  
230 of-service threat may represent a high impact for time-sensitive disease surveillance but a low  
231 impact for an agricultural researcher. To maximize the applicability of this paper’s use case  
232 (sequencing genomic material), the process focuses on threats instead of risks, which are  
233 specific to the organization and its use case. The term “threat” is not the same as “risk.”

- 234 • A threat is “any circumstance or event with the potential to adversely impact  
235 organizational operations (including mission, functions, image, or reputation),  
236 organizational assets, or individuals” [\[5\]\[6\]](#).
- 237 • A risk is “a measure of the extent to which an entity is threatened by a potential  
238 circumstance or event, and typically a function of: (i) the adverse impacts that would  
239 arise if the circumstance or event occurs; and (ii) the likelihood of occurrence” [\[5\]\[7\]](#).

240 Threat modeling scenarios are adaptable to different stakeholders who can bring to the threat  
241 model their specific organization-dependent (i) adverse impact and (ii) likelihood of occurrence  
242 of the threat that are required to calculate their risk. Threat modeling scenarios can even  
243 accommodate different risk and vulnerability assessments beyond that described above as may  
244 be appropriate for different use case scenarios (e.g., for the use case of a medical device  
245 manufacturer submitting a device for the U.S. Food and Drug Administration (FDA) clearance  
246 [\[8\]](#)).

247 The determination of the potential risk will guide an organization in their risk strategy to  
248 eliminate, mitigate, accept, or transfer responsibility for threats to meet their organization’s  
249 specific risk tolerance and applicable legal or regulatory requirements.

***Organizational risk can be defined as a combination of the likelihood of occurrence of  
threat becoming realized and the impact that it has on the organization.***

250

### 251 1.4. Threat Modeling Overview

***The threat modeling process identifies cybersecurity objectives and vulnerabilities across  
the system and defines countermeasures to eliminate, mitigate, accept, or transfer  
responsibility for threats throughout the system’s lifecycle.***

252

253 The NCCoE team used the Four Question Framework [\[7\]](#), illustrated in Figure 2, to structure the  
254 threat modeling process by answering:

- 255 1) What are we working on?
- 256 2) What could go wrong?
- 257 3) What are we going to do about it?
- 258 4) Did we do a good job?

259 Though the questions are listed in sequential order, the process is iterative, as shown by the  
260 arrows in the figure. Each question is addressed through specific techniques outlined in this  
261 paper. Answers to one question may be used to modify previous answers or highlight the  
262 incompleteness of an answer to a previous question.

263 Since some genomic sequencers are regulated as medical devices when used as *in vitro*  
264 diagnostic products as defined in 21 CFR Part 809.3, this paper uses the threat modeling  
265 approach described in the *Playbook for Threat Modeling Medical Devices (Playbook)* [\[9\]](#) that is  
266 based on methods described in the “Threat Modeling Manifesto” [\[10\]](#). The FDA, in its  
267 premarket guidance for cybersecurity in medical devices [\[8\]](#), refers to a threat modeling  
268 methodology and recommends that medical device manufacturers implement threat modeling  
269 to analyze and identify security concerns in medical devices. The Playbook can also be used as a  
270 guide to conduct threat modeling by organizations who are not medical device manufacturers,  
271 as is the case in this paper.


272 Because this threat model is intended for various stakeholders who have differing risks to the  
273 same threats, some possible mitigations will be suggested. However, organizations will choose  
274 specific mitigations depending on their mission, their goals in performing the threat modeling  
275 process, the risks associated with the specific use case, the phase of the system lifecycle, and  
276 the resources at their disposal. Therefore, a comprehensive list of mitigations and answers to  
277 Question 4 will not be provided in this paper. [Section 2.3](#) provides potential mitigations  
278 reflective of common threats and implementations seen in the genomic workflow. Individual  
279 organizations can translate threats into risks by incorporating mission and use case-specific  
280 probabilities and impacts. The calculated risks can help them choose whether to mitigate,  
281 accept, transfer, or eliminate the specific threats.

## 282 **1.5. Audience**

283 This paper is intended for organizations that process genomic datasets. Organizations that  
284 sequence genomic material, analyze genomic datasets, or transfer genomic data files can apply  
285 a similar threat modeling process, including the sample architecture diagrams, threats  
286 identified, suggested mitigations, and other findings from this paper to help them identify and  
287 address similar threats in their environments.

## 288 2. Threat Modeling Example

289 This section applies the *Playbook* methodology [9] to provide an example of how to conduct  
290 threat modeling on the genomic sequencing workflow using the Four Question Framework  
291 (Figure 2). For completeness, we include Tables 2, 3, and 4 from the *Playbook* [9] to guide the  
292 interpretation of system architecture diagrams that describe the sequencing workflow. We  
293 refer readers to the *Playbook* and the Shostack website<sup>4</sup> for more threat modeling examples  
294 and thorough descriptions that extend beyond genomics.



295 Figure 2. Visualization of the Four Question Framework for Threat Modeling [11]

### 296 2.1. Question 1: What are we working on?

297 Answering Question 1 helps teams identify activities and language to better understand and  
298 describe the system(s) being analyzed. This involves reviewing the system, interviewing  
299 associated personnel, analyzing architecture documents, and building out the use case to  
300 develop a shared understanding of the system components, functionality, and interfaces.  
301 Through this process, the team establishes a baseline understanding that will support analyzing  
302 cybersecurity threats against the system, evaluating the effectiveness of cybersecurity  
303 mitigations, and characterizing the resilience of the system.

304 This section identifies and characterizes the system and data of interest using Dataflow  
305 Diagrams (DFDs) and High-Value Dataflows (HVDs). First, we describe the diagramming  
306 techniques and then apply those techniques to provide example diagrams for both the  
307 Genomic Sequencing Laboratory and Research Partner environments.






308 **Dataflow Diagrams.** The team developed DFDs to document “What are we working on?” The  
309 DFDs depict trust boundaries and communication paths between different components of the

<sup>4</sup> <https://shostack.org>

310 system being analyzed. This technique was selected due to the “system of systems” nature of  
311 the use case, since DFDs highlight interactions among external entities and trusted  
312 components. DFDs also facilitate the Spoofing, Tampering, Repudiation, Information Disclosure,  
313 and Escalation of Privileges ([STRIDE](#)) threat analysis, a technique that will be described under  
314 Question 2. DFDs help teams produce a common architecture document that can be used for  
315 other collaboration and development activities outside the threat modeling effort.

316 The format of these dataflow diagrams follows conventions established in the *Playbook* and  
317 repeated here in Table 2.

318 **Table 2. Symbols Used in Detailed DFDs**

Element	Symbol	Discussion
External Entity		<b>Object:</b> A sharp-cornered rectangle. <b>Represents:</b> Anything outside your control. Examples include people and systems run by other organizations or even divisions.
Process		<b>Object:</b> A rounded rectangle. <b>Represents:</b> Any running code, including compiled, scripts, shell commands, Structured Query Language (SQL) stored procedures, et cetera.
Data Store		<b>Object:</b> A drum. <b>Represents:</b> Anywhere data are stored, including files, databases, shared memory, cloud storage services, cookies, et cetera.
Dataflows		<b>Object:</b> A double-headed arrow. <b>Represents:</b> All the ways that processes can talk to data stores or each other. If a conversation is only initiated by one side, you can represent the initiating side as an empty arrow.
Trust Boundary		<b>Object:</b> A closed shape drawn with a dashed or dotted line. <b>Represents:</b> A way to display different trust levels between objects.

319 Each rectangle with dotted lines represents a **trust boundary**. Each rectangle with solid lines  
320 represents a **component**. All stick figures represent **human actors** in the environment. All lines  
321 connecting components or actors represent **dataflows** that can be either digital or physical  
322 (such as a network connection or a human inserting a physical sample into the sequencer).  
323 Dataflows that were determined to be HVDs are labeled with a "D" followed by a number and  
324 are shown in a **darker line** than other dataflows. Dataflows are shown as double-headed  
325 arrows. A **hollow arrow** on one side of a given dataflow implies that the component or process  
326 on that side of the dataflow is the initiator of the communication.

327 **High Value Dataflows.** Some DFDs, called HVDs, were selected for more detailed analysis  
328 because they significantly impact the system’s security and resiliency, as described in [Section](#)  
329 [2.1.3](#). While DFDs help identify which components and processes share data, they do not  
330 capture the details of how protocols and organizational use cases operate. To get to that level  
331 of detail for HVDs, this paper leveraged cross-functional swim lane diagrams.

332 [Figure 1](#) illustrates interactions between the Research Partner and the Genomic Sequencing  
333 Laboratory to transfer, sequence, and analyze genomic data. The use case can be applied to  
334 interactions with other external entities that may include equipment manufacturers, untrusted  
335 software, and cloud providers. The following sections provide examples of DFDs and HVDs for  
336 both the Genomic Sequencing Laboratory and the Research Partner.

### 337 **2.1.1. Genomics Sequencing Laboratory Data Flow Diagrams**


338 The **Genomic Sequencing Laboratory** consists of multiple environments and boundaries that  
339 work together to process, analyze, and transfer genomic data. The systems involved in the  
340 transfer can be physical or virtual, ranging from laboratory equipment and genetic sequencers  
341 to virtualized applications or cloud storage and services.

342 Figure 3 illustrates the high-level architecture of the Genomic Sequencing Laboratory’s  
343 boundaries, environments, and systems, using an identifier (ID) to reference each component.  
344 The Genomic Sequencing Laboratory environments each have their own trust boundary.

345 Example environments include a Wet Lab with sequencing (ID: C1), a Management and Tooling  
346 environment (ID: C3), a Research and Computing environment (ID: C10), and a Data Delivery  
347 Demilitarized Zone (DMZ) environment (ID: C21) for controlling access to the storage  
348 environment from outside entities. These separate but integrated environments process  
349 physical DNA samples that become genomic data in the form of raw data, metadata,  
350 intermediate processed data, and reports. Genomic data can be transferred between  
351 environments and across trust boundaries.

352 The Remote Access and External Actors trust boundary can be found at the top of the diagram.  
353 This trust boundary includes all entities external to the Genomic Sequencing Laboratory  
354 network that are anticipated to connect to the lab’s network. Common examples of external  
355 entities include the National Institutes of Health (NIH) National Center for Biotechnology  
356 Information (NCBI), as well as Software as a Service (SaaS) or Platform as a Service (PaaS)  
357 applications used by the lab.





358 **Figure 3. High-Level Architecture of the Genomics Sequencing Laboratory**

359 Because of its complexity, more detailed DFDs of the Genomics Laboratory are presented  
360 separately for readability and clarity (ID.AM-03; MO:1,8) in Figures 4 through 7.

361 Figure 4 represents a more detailed DFD of the **Wet Lab** (ID: C1) and its associated process. The  
362 Wet Lab contains the equipment necessary to analyze physical DNA samples, digitize the  
363 genomic information, and combine the data with the Laboratory Information Management  
364 System (LIMS) digital data (ID: C2) that identifies the physical sample. This includes equipment  
365 used during the DNA Extraction (ID: C3), DNA Fragmentation (ID: C4), Library Preparation (ID:  
366 C5), Quality Control (ID: C6), and sequencing phases of the genomic data lifecycle. The flows of  
367 data between these components of the Wet Lab are shown as connections between  
368 components on the diagram. The Lab Technician (ID: C7) and the Manufacturer Maintenance  
369 Technician (ID: C8) are shown as well, as they interact directly with Wet Lab systems and are  
370 within the Wet Lab trust boundaries.





Figure 4. Wet Lab DFD

371


372 Figure 5. Sequencer DFD shows the **Sequencer** (ID: C9) with much more detail regarding  
373 internal logical components in comparison with other Wet Lab equipment. We highlighted the  
374 Sequencer (ID: C9) as a device of interest to the threat modeling effort due to the complexity,  
375 high cost, and comparatively large threat surface within the Wet Lab. The Sequencer is the  
376 device in the Wet Lab network that converts a physical sample into digital DNA sequence data.  
377 The Sequencer allows direct connections from the Manufacturers (ID: C26) at all times for the  
378 purposes of remote maintenance. This always-available connection introduces potential  
379 security threats.  
380 Once the DNA sequence data leaves the Wet Lab, it travels to the Cluster Filesystem (ID: C11)  
381 within the Research Computing (ID: C10) environment, where the data are then stored.



382


Figure 5. Sequencer DFD

383 Figure 6 provides more details for the Data Delivery DMZ (ID: C21), Management and Tooling (ID: C13), and Research Computing (ID: C10) environments. Data are delivered from the  
384 Sequencer to a restricted area on the Cluster Filesystem (ID: C11) within the Research  
385 Computing Environment. The Quality Control (QC) analysis (ID: C12) can perform operations on  
386 the data within this restricted area on the Cluster Filesystem. When ready, the data are copied  
387 from the restricted location on the Cluster Filesystem to an area on the Cluster Filesystem that  
388 can be accessed by the Data Delivery DMZ (ID: C21) for delivery to an external entity.  
389



390 **Figure 6. Data Transfer DFD**

391 Figure 7 depicts the environment that houses Monitoring and Security Logs (ID: C14b), Cyber  
392 Tooling (ID: C15d), Administration (Admin) and Information Technology (IT) or Admin/IT Tooling  
393 (ID: C15b), and Sequencer Management (ID: C15c). In one embodiment, these would be virtual  
394 machines (VMs) running on a server that has a Hypervisor (ID: C16).




395 **Figure 7. Management and Tooling DFD**

396 **2.1.2. Research Partner Data Flow Diagrams**

397 Figure 8 illustrates a high-level architecture of the **Research Partner** environment. The main  
 398 system of interest for the Research Partner is the Compute Server (ID: 101). Threats against the  
 399 confidentiality, integrity, and availability of this system are of particular importance to the  
 400 Research Partner threat model, as this is the system where bioinformatics analysis takes place  
 401 using sensitive genomic data that is stored on the server.

402 The Research Partner environment connects to external entities, including the Genomic  
 403 Sequencing Laboratory (ID: 108) to sequence the data, Manufacturer Updates (ID: 127) for  
 404 updates to the operating system (OS), Untrusted Software Packages (ID: 104) used for genomic  
 405 analysis, and Genomic Reference Resources (ID: 105) required for genomic analysis.




406 **Figure 8. High Level DFD for Research Partner**

407 Figure 9 illustrates a more detailed architecture of the Research Partner environment with  
408 associated personnel and external connections (ID.AM-03; MO:1,8). An administrator who  
409 performs OS and IT Setup (ID: 130) manages the server and endpoint protection of the server. A  
410 Bioinformatics Analyst (ID: 131) uses the server for genomic analysis and may initiate transfers  
411 of data or software between trust boundaries.

412 Each of the external entities identified introduces potential threats to be considered from the  
413 perspective of the Research Partner environment (ID.AM-04; MO:1,8). Some of the external  
414 entities are likely more trusted (such as NIH/NCBI or Globus<sup>5</sup>) than others. Some OSS projects  
415 are security conscious and follow best practices such as the recommendation of the Secure  
416 Software Development Framework (SSDF) [12], including inviting the public to review the code  
417 for security vulnerabilities and submit improvements. However, some OSS may be considered  
418 less trusted if it does not follow SSDF recommendations, resides in publicly accessible  
419 repositories without secure access and change control, or has maintenance that is  
420 heterogenous depending on the career trajectory of the researchers that initially develop the  
421 software.

422 Dataflow D102 in Figure 9 connects the Globus Transfer Client (ID: 123) with the Data Delivery  
423 DMZ (ID: 126), also labeled as ID: C21 in Figure 6. This represents that the Globus Server  
424 Connect application is running in the Data Delivery DMZ (ID: 126) of the Genomic Sequencing  
425 Laboratory, and the Globus Personal Connect Client is running on the Server (ID: 101).



426 **Figure 9. Detailed DFD of Research Partner**

<sup>5</sup> Globus is research cyberinfrastructure for securely moving, sharing, and discovering data, developed and operated as a nonprofit service by the University of Chicago: <https://www.globus.org/what-we-do>. For technical details, see <https://docs.globus.org/guides/recipes/modern-research-data-portal/>.

### 427 2.1.3. High-Value Dataflows Overview

428 DFDs are useful for depicting which components communicate with each other, but they are  
429 static models that do not capture the details of how protocols and use cases operate. DFDs can  
430 be used to identify HVDs that merit detailed analysis using different modeling techniques. This  
431 section describes the use of HVDs as a modeling technique and identifies six example HVDs,  
432 three from the Genomic Sequencing Laboratory and three from the Research Partner (ID.RA-05;  
433 MO:1,3,8). Comprehensive threat modeling, as may be needed to comply with regulatory  
434 requirements, will address all HVDs in a similar way to the six specific examples in this paper.

435 In our documentation, HVDs are processes or use cases based on areas of interest, often  
436 because they were highlighted in the *Playbook*, cross trust boundaries, perform a critical  
437 function, or access a critical system. HVDs tend to be high risk and have a high impact if they  
438 are compromised.

***DFDs can be designated as HVDs when they cross trust boundaries, perform a critical function, or access a critical system.***

439  
440 Examples of HVDs from the *Playbook* that are relevant to this system include:

- 441 • Authentication protocols
- 442 • Programming and configuration commands
- 443 • Obtaining and validating software updates
- 444 • Procedures to restore from backups

445 Modeling techniques of system state can be helpful to describe how the system will be used,  
446 the different modes it may find itself in, and how the system handles error states and invalid  
447 input. For example, a genomic sequencer may behave differently if it is in a sequencing mode  
448 versus a service mode. One modeling technique that can be useful is a cross-functional swim  
449 lane diagram. This paper leveraged cross-functional swim lane diagrams to document the  
450 details of processes and use cases that were identified as HVDs, potentially having a large  
451 impact on the security or resiliency of the system.

452 The selection of HVDs was guided by the following considerations:

- 453 • The *Playbook* has a brief list of HVDs for medical devices. When used for clinical  
454 diagnostics, a high throughput genomic sequence analyzer is regulated as a Class 2  
455 medical device [13], so all HVDs listed in the *Playbook* were carefully considered.
- 456 • Dataflows that cross multiple trust boundaries also received consideration to be  
457 selected as an HVD, as traditionally these types of dataflows have large attack surfaces  
458 and are often entry points for adversaries.
- 459 • The most valuable assets in both the Genomic Sequencing Laboratory and the Research  
460 Partner were the genomic data. In the Genomic Sequencing Laboratory environment,  
461 the data reside on the Cluster Filesystem (ID: C11), and in the Research Partner  
462 environment, the Data Storage on Server (ID: 103) (ID.AM-05; MO:1,3). Thus, dataflows  
463 that interacted with either of these highest-value data were identified as key HVDs.

#### 464 **2.1.4. Genomic Sequencing Laboratory HVD Examples**


465 The diagrams that follow are a subset of the identified HVDs from Figures 4 through 7. These  
466 examples provide more detailed cross-functional diagrams with accompanying text to  
467 demonstrate the detail needed to answer Question 1 (“What are we working on?”) in sufficient  
468 detail so that it can provide the required input to Question 2 (“What can go wrong?”) of the  
469 threat modeling process.

##### 470 **2.1.4.1. Example HVD 1**

471 The first important HVD considered in the Genomics Sequencing Laboratory architecture is the  
472 connection between the Cluster Filesystem (ID: C11) within the Research Computing  
473 Environment and the Data Delivery DMZ (ID: C21) for controlling access to the storage  
474 environment from outside entities. This dataflow is labeled as D6 in Figure 6 DFD. Because it  
475 hosts the genomic data sequences, the Cluster Filesystem is one of the most valuable assets of  
476 the Genomic Sequencing Laboratory environment. The Data Delivery DMZ is important to  
477 consider because it is exposed to the hostile internet.

478 Figure 10 diagrams the data transfer process where an administrator in charge of fulfilling data  
479 requests for Research Partners requests a list of available files from the Cluster Filesystem. The  
480 Cluster Filesystem provides the files after it checks whether the administrator has the necessary  
481 permissions to read and publish the files. Then the administrator selects which files should be  
482 copied to the Data Delivery DMZ-accessible folder, and the Cluster Filesystem copies the files  
483 into an area for Research Partners via the Data Delivery DMZ.






484

**Figure 10. HVD 1: Cluster Filesystem to Data Delivery DMZ**

485 **2.1.4.2. Example HVD 2**

486 The second important HVD considered is labeled D1 in [Figure 5](#), the connection between the  
 487 Manufacturer (ID: C26) and the Remote Maintenance Interface (ID: C9f) of the sequencer. This  
 488 connection is used, among other things, for sequencer software updates. This is considered an  
 489 HVD because the entire use case relies on the integrity and data quality of the sequencing. The  
 490 Cluster Filesystem within the Research Computing Environment also trusts the integrity and  
 491 data quality of the sequencer. Additionally, the connection to the manufacturer happens via  
 492 the untrusted internet, and some manufacturers and/or their service departments may be in a  
 493 country or location of concern for the organization. Organizations should evaluate the risks  
 494 from equipment, software, and processing that involve locations of concern.

495 Figure 11 illustrates the cross-functional diagram as an example of a process that a  
 496 manufacturer might use in updating the sequencer software. The manufacturer first connects  
 497 to the sequencer and provide the necessary credentials for the sequencer to authenticate.  
 498 After successful authentication, the manufacturer sends the updated binary file and installs it  
 499 on the sequencer. The session concludes with the manufacturer verifying that the update was  
 500 successful and that the sequencer is functioning properly.




501 **Figure 11. HVD 2: Sequencer Remote Interface to Manufacturer**

502 **2.1.4.3. Example HVD 3**

503 The connection between the Sample Output Interface (ID: C9b) from the Wet Lab sequencer  
 504 and the Cluster Filesystem (ID: C11) [labeled as D2 in Figure 5] within the Research Computing  
 505 Environment is the third HVD diagramed. This dataflow connects the two most valuable  
 506 components of the environment with the data flowing across a trust boundary. Depending on  
 507 the configuration, the sequencer may be trusted by the Cluster Filesystem and vice versa.

508 Figure 12 illustrates the cross-functional diagram for this HVD in more detail. The sequencer  
 509 sequences a sample. When finished, it checks whether the results have any errors. If not, it  
 510 sends the data to the Cluster Filesystem when a network connection exists with the Wet Lab  
 511 sequencer. If there is no network connection, the sample output interface temporarily saves  
 512 the data to secondary storage. The sequencer may be trusted by the Cluster Filesystem.



513 **Figure 12. HVD 3: Sequencer to Cluster File System**

514 Other HVDs in Figures 4 through 7 could be included in the threat modeling but were not  
515 described as one of the three examples of Genomic Sequencing Laboratory HVDs. Sorted by  
516 figure, these include:

- 517 • **Wet Lab** (Figure 4) HVD D11: The Sample Intake (ID: C2) is where the lab receives the  
518 highly valuable physical genomic sample and shares the sample metadata with  
519 Applications and Services (ID: C15c).
- 520 • **Sequencer** (Figure 5) HVD D3, D4, D12, D13, D14: The sequencer dataflows crossing  
521 trust boundaries include HVD D3—remote Sequencer Management (ID: C15c) and HVD  
522 D12—the connection between the Sample Output Interface (ID: C9b) and SaaS/PaaS (ID:  
523 C27) storage. HVD D4 identifies the user interface to the Sequencer (ID: C9) from the  
524 Sequencer Control Workstation (ID: C9c), which may be either a separate workstation or  
525 integrated with the sequencer. HVD D13 and D14 capture software updates to the  
526 sequencer, including those made by the Manufacturer Maintenance Technician (ID: C8)  
527 and IT Staff Administrator (ID: C18).
- 528 • **Data Delivery DMZ** (Figure 6) HVD D5, D6, and D7: These connections to the Data  
529 Delivery DMZ (ID: C21) include IT Staff Administrator (ID: C18) who initiate data  
530 transfers in Globus, storage to the Cluster Filesystem (ID: C11), and dataflows with  
531 Partners (ID: C22).
- 532 • **Management and Tooling** (Figure 7 **Error! Reference source not found.**) HVD D8, D9, a  
533 nd D10: These connections to the Management and Tooling environment (ID: C13)  
534 include HVD D8—the external connection to third-party Partners (ID: C22), HVD D9—the  
535 remote administrative access of the Compute Nodes (ID: C12), and HVD D10—  
536 application and services connections to confidential internal data (ID: C14).

#### 537 **2.1.5. Research Partner HVDs**


538 This section provides examples of HVDs and cross-functional diagrams for the Research Partner  
539 environments. The location of the HVDs in the environment is shown by bold connections  
540 labeled D101 through D105 in Figure 9.

##### 541 **2.1.5.1. Example HVD 4**

542 The fourth example of an HVD (D101 in Figure 9) in a bioinformatics analysis environment is the  
543 identification, installation, and use of untrusted research software by the Research Partner.  
544 Many research conferences and articles detail newly available software, along with GitHub links  
545 or other download mechanisms. This software then runs directly on the high-value genome  
546 sequencing data. Figure 13 illustrates the cross-functional diagram for this process.

547 The researcher identifies the new research software to use and the location where it is stored.  
548 The researcher then identifies an appropriate configuration of access rights granted through a  
549 policy enforcement module (e.g., as referenced in Figure 13 by the use of an AppArmor or  
550 SELinux profile) that limits the software's privileges and processes to only those that are  
551 appropriate to perform its function.

552 After connecting to the server with Secure Shell (SSH), the researcher either uses the  
553 appropriate profile identified to create a container for the software or develops a new profile  
554 by logging requests that the application will use. After creating the container with the  
555 appropriate profile, the software is installed in the container and access is given to the  
556 container with the genomic data that the researcher wants to process with the new research  
557 software. As an added precaution, the software distribution system performs software testing  
558 that includes scanning for malware prior to use.




559 **Figure 13. HVD 4: Example of a Method of Running Untrusted Software on Genomic Data**

560 **2.1.5.2. Example HVD 5**

561 Figure 14 identifies the fifth HVD for consideration, labeled as D105 in Figure 9. This HVD  
562 includes the processes used to back up sequencing data files for recovery after an equipment  
563 failure or from a ransomware attack. The genomic data are of great value to the Research  
564 Partner, representing a significant cost to replace. However, the genomic datasets can be very  
565 large, so typical enterprise backup solutions may not suffice.


566 As shown in Figure 14, a user starts the process by receiving a notification from a scheduled  
567 backup (the “cron job”) that genomic data in their local storage is out of sync with backup data.  
568 This cron job alerts a user that no backup has taken place or that these data are not properly  
569 accounted for in a backup. The user will then connect to the server to determine if the data  
570 that needs to be backed up are encrypted. If encrypted, the user will transfer the encrypted  
571 data to the backup service. If the data are not, the user will need to encrypt the data. That data  
572 encryption will also represent an HVD because of the value of protecting the encryption keys.



573 **Figure 14. HVD 5: Backing up Sequencing Data to Cloud Storage**

574 **2.1.5.3. Example HVD 6**

575 Figure 15 illustrates the sixth HVD, the receipt of genomic sequencing data from a Research  
 576 Partner, labeled as D102 in Figure 9. Securely transferring data between a Research Partner and  
 577 a Genomic Sequencing Laboratory environment, in this case, is mediated by the Globus  
 578 research transfer service. Figure 15 illustrates this scenario where a user receives a  
 579 communication, such as an email from the Research Partner, that data are ready for transfer  
 580 from an agreed-upon transfer endpoint. The user authenticates with Globus and initiates the  
 581 data transfer to the server using the Globus GridFTP user interface (UI) with the "encrypt  
 582 transfer" option selected. Upon receiving the Globus transfer completion notification, the user  
 583 verifies the signature of the file (which mitigates a tamper threat in [Section 2.2.2](#) described  
 584 below) to ensure the integrity of the data (PR.DS-01: MO:1,3,8). The data can then be used for  
 585 analysis.



586 **Figure 15. HVD 6: Obtaining Genomic Data from Genomic Sequencing Laboratory**

587 Other HVD flows identified in Figure 9 but not described as one of the six HVDs above include:

- 588 • HVD D103: The dataflow between the Research Partner (ID: 109) and publicly available  
589 Genomic Analysis Resource Providers (such as the NIH/NCBI) (ID: 118) that contain  
590 reference genomes and annotations.
- 591 • HVD D104: Updates to the Research Partner Server (ID: 110) OS through the OS IT Setup  
592 (ID: 130).
- 593 • HVD D106: Storing and encrypting the genomic data at rest, either on local Genomic  
594 Data Storage (ID: 111) or for Backups (ID: 113). Here the organization should decide  
595 whether to encrypt and how users will manage keys to decrypt.

## 596 **2.2. Question 2: What could go wrong?**

597 After DFDs were prepared, HVDs were identified, and the question “What are we working on?”  
598 seemed to be adequately addressed, work began on the second question, “What could go  
599 wrong?” While the *Playbook* details several techniques for identifying threats, the team used  
600 two methodologies, [STRIDE](#) and attack trees based on [MITRE ATT&CK](#) Tactics, Techniques, and  
601 Procedures (TTPs). Note that as the team worked on question 2, it sometimes revealed that  
602 question 1 needed additional details added for completeness.

603 The STRIDE and MITRE ATT&CK methodologies were supplemented by determining priorities  
604 from the stakeholders that identified resources that were the most important to protect. For  
605 the Research Partner, the genomic datastore was prioritized as the most valuable element to  
606 protect. For the Genomics Sequencing Laboratory, the genomic datastore was also considered  
607 the most important asset, followed closely by the genomic sequencer (some stakeholders might  
608 reverse the importance of the two). The genomic sequencer is expensive and a key part of the  
609 revenue generation of commercial laboratories. These identified high-value assets were used to  
610 prioritize the key STRIDE threats and to identify the assets targeted by the attack trees.

### 611 **2.2.1. Spoofing, Tampering, Repudiation, Information Disclosure, and Elevation of Privilege** 612 **(STRIDE)**

613 The STRIDE methodology involves identifying and organizing threats from these six STRIDE  
614 elements (or categories) against individual components of the system being analyzed.  
615 Sometimes threats overlap categories. For example, ransomware that encrypts data and  
616 requires payment for the encryption key could be classified as either tampering or denial of  
617 service. During this exercise, capturing the threat is more important than classifying it as one  
618 type of STRIDE element or another.

619 The STRIDE methodology does not rely upon analyzing past attacks and disclosures. This makes  
620 STRIDE well-suited for understanding potential future threats for newly developed systems and  
621 capabilities. Table 3 describes the STRIDE elements and provides genomic examples for each  
622 element.

623

**Table 3. STRIDE Mnemonic with Examples<sup>6</sup>**

STRIDE Element	Description	Example
<b>Spoofing</b>	Tricking a system into believing a false entity is a true entity	Using stolen or borrowed credentials to log on as an authorized researcher
<b>Tampering</b>	Intentional modification of a system or data in an unauthorized manner	Modifying genomic data to stealthily add pathogenicity
<b>Repudiation</b>	Disputing the authenticity of an action taken	Denying that you accessed other researchers' genomic data
<b>Information Disclosure</b>	Exposing information intended to have restricted access levels	Publishing a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) guide Ribonucleic Acid (RNA) sequence that is a trade secret in commercial development
<b>Denial of Service (DoS)</b>	Blocking legitimate access to the functionality of a system by malicious process(es)	Sending a Transmission Control Protocol (TCP) packet flood to prevent genomic data transfer between systems on the internet
<b>Elevation of Privilege (EoP)</b>	Gaining access to functions to which an attacker should not normally have access according to the intended security policy	A researcher using a vulnerability in a genomic data transfer web portal to access other researchers' genomic data, rather than just their own

624 STRIDE has the advantage of being very structured and can improve brainstorming by ensuring  
 625 DFD elements (such as processes, datastores, dataflows, and external entities) are not ignored.  
 626 It can be used by threat modelers of all experience levels to identify threats to the system  
 627 independent of selecting effective mitigations. However, often there are costs to mitigations,  
 628 and STRIDE's weakness is that it fails to tell a story of how a threat might represent a real risk.  
 629 For example, the threat may be difficult to exploit because of other mitigations that an attacker  
 630 would need to bypass to get to the process or dataflow that the threat is against. The STRIDE  
 631 methodology does not inform prioritization of mitigations and justifying cost or risk trade-offs.  
 632 The *Genomic Data Profile* [4] or attack trees can be used to prioritize mitigations.

633 The STRIDE analysis was performed for the detailed DFDs of the Genomic Sequencing  
 634 Laboratory and the Research Partner. The team iterated the analysis as the understanding and  
 635 models were refined.

636 Each component was given a unique component identifier (Component ID). Every threat against  
 637 a component was given a unique identifier as well (Threat ID) and classified as one of the six  
 638 STRIDE threats. No attempt was made to sequentially or otherwise assign the Component or  
 639 Threat IDs, except to keep them unique. Figure 16 illustrates the format of the table elements  
 640 for the STRIDE analysis. Each row includes the component and unique threats identified against  
 641 that element.

<sup>6</sup> Reproduced from the *Playbook* [9] and modified with genomics examples.

Component Name/ID	Spoof	Tamper	Repudiate	Info Disclosure	DoS	EoP
Remote Maintenance Interface (ID: 9f)		47	48		49a, 49b	50
Local Temporary Datastore (ID: 9g)		51		52	53	
Data Delivery DMZ (ID: 21)	54	55	56a, 56b	57	58	
Archival Storage - S3 (ID: 21a)	59	60	61a, 61b	62	63	
Globus (ID: 21b)	64	65	66a, 66b	67	68	
Research Computing Environment (ID: 10)	69	70	71a, 71b	72	73	74
Cluster Filesystem (ID: 11)		75		76	77	

**Figure 16. Portion of the STRIDE Table Demonstrating Format**

642

643 This figure facilitated threat tracking and can be used in conjunction with Table 12 to validate  
644 that all appropriate STRIDE threats were evaluated for each data element. The actual threats  
645 represented by the Threat IDs were in a separate table, with the first column being the Threat  
646 ID and the row describing the details of the threat.

### 647 2.2.2. Key STRIDE Results

648 The threats identified in the STRIDE analysis (see Table 4 and Table 5) were analyzed and  
649 prioritized based on real-world data and attacks that targeted the most valuable assets  
650 identified in [Section 2.2](#). This section presents several examples of the “key” STRIDE threats  
651 while not implying that these threats are the only ones that need to be mitigated. All threats  
652 need to be addressed through elimination, mitigation, acceptance, or transfer. The process for  
653 addressing threats should consider likelihoods and impacts (ID.RA-05; MO:1,3,8) as well as any  
654 legal or regulatory requirements.

655 These ten key STRIDE threats were mapped to TTPs from the MITRE ATT&CK Framework for  
656 [Industrial Control Systems](#) (ICS) or [Enterprise Systems](#), though this was not done for all threats  
657 identified. Threats that include MITRE ATT&CK TTPs have been observed being used by  
658 adversaries. Hypothetical threats and threats that have only been realized in a research setting  
659 are not included in the MITRE ATT&CK Framework.

660 In the following tables, each STRIDE threat is identified along with a brief explanation of how  
661 the threat could be exploited and why it could be particularly impactful. Table 4 describes the  
662 STRIDE threats specific to genomic sequencers and provides a link to the MITRE ATT&CK  
663 Technique for additional information.

664

**Table 4. STRIDE Threats Specific to Genomic Sequencers**

STRIDE Threat and MITRE ATT&CK Technique	Description
<b>1. Genomic Sequencer Tampering via the Attached Workstation</b> MITRE ATT&CK Technique(s): <a href="#">T0884</a> – Connection Proxy	The Genomic Sequencer implicitly trusts the attached workstation. This trust relationship between the Genomic Sequencer and the attached workstation could be exploited to tamper with the Genomic Sequencer.
<b>2. Genomic Sequencer Tampering with Genomic Data on the Cluster Filesystem.</b> MITRE ATT&CK Technique(s): <a href="#">T0867</a> – Lateral Tool Transfer <a href="#">T0884</a> – Connection Proxy	The Genomic Sequencer is generally trusted by the Cluster Filesystem, and this elevated privilege makes it a target for a malicious actor. If the Genomic Sequencer has read/write access it could tamper with (for example, encrypt during a ransomware attack) the entire datastore. An attack tree for this threat is shown in Figure 18.



STRIDE Threat and MITRE ATT&CK Technique	Description
<b>3. Local Secondary Storage Information Disclosure and Exfiltration</b> MITRE ATT&CK Technique(s): <a href="#">T0893 – Data from Local System</a>	A malicious actor could obtain and exfiltrate data from the Genomic Sequencer’s local secondary storage that temporarily stores sequence data during network outages
<b>4. Spoofing of Sequencer Management Control of the Lab Network Administration Interface</b> MITRE ATT&CK Technique(s): <a href="#">T0858 – Change Operating Mode</a>	The communication between the Sequencer Management application from the Hosting Environment to the Genomic Sequencer’s Lab Network Administration Interface allows for remote management of sequencer runs. For this threat, a malicious actor spoofs coming from the Sequencer Management application and sends malicious sequencer management instructions over a remote access connection to the Lab Network Administration Interface of the Genomic Sequencer. If these instructions are perceived as originating from the Sequencer Management application, they could disrupt the Genomic Sequencer's scheduled runs, disclose information about these runs, extract sequencing data, or even permanently incapacitate expensive laboratory equipment, including DNA sequencers

665 Table 5 describes threats to the Genomics Sequencing Laboratory or Research Partner  
 666 environments. Each threat has been mapped to MITRE ATT&CK Techniques for additional  
 667 information.

668 **Table 5. STRIDE Threats to the Genomic Sequencing Laboratory or Research Partner Environments**

STRIDE Threat and MITRE ATT&CK Technique	Description
<b>5. Tampering of Data from Research Partner Datastore by Bioinformatic Software</b> MITRE ATT&CK Technique(s): <a href="#">T1195 – Supply Chain Compromise</a>	Bioinformatic software are vulnerable to malware injection. While vulnerability concerns exist in other domains, the bioinformatics tools supply chain is often funded through multi-year research grants, after which software maintenance is minimal, if completed at all, as developers move to other projects or career positions. Vulnerabilities such as poor sanitation of inputs and use of obsolete or insecure functions with known exploitations have been identified [14][15]. Bioinformatics code developers may also introduce vulnerabilities through insecure code re-use or by including dependencies that can be exploited. An attack tree for this threat is shown in Figure 18.
<b>6. Tamper or Exfiltration of Research Partner Data through Remote Access to a Datastore</b> MITRE ATT&CK Technique(s): <a href="#">T1078 – Valid Accounts</a> <a href="#">T1133 – External Remote Services</a> <a href="#">T1021 – Remote Services</a>	Research environments need remote access to the internet to connect with a datastore (for example, Globus) and download software packages. Adversaries may connect to a Research Environment datastore through remote access. They may leverage valid accounts or open external remote services to tamper with and/or exfiltrate genomic data or subsequent analyses.
<b>7. Data Exfiltration from a Research Partner Datastore by Bioinformatic Software</b>	Genomic datastores, especially those that contain data from individuals with pharmaceutical-targetable diseases, are of significant value. Whole genome sequencing runs are costly (at least \$1,000 per sample) and samples are difficult to obtain. The threat here is similar to what was previously described above as threat “5,” though instead of ransomware, the motive for inserting

<b>STRIDE Threat and MITRE ATT&amp;CK Technique</b>	<b>Description</b>
<b>MITRE ATT&amp;CK Technique(s):</b> <a href="#">T1567 – Exfiltration over Web Service</a>	malicious code into a bioinformatics software package could be data exfiltration. Common approaches to genome analysis often involve combining several bioinformatics software packages to process the data. Some software may also need external connections to reach external databases for additional information or resources. Thus, the software needs a connection to the internet, enabling an exfiltration threat. An attack tree for this threat is also shown in Figure 17.
<b>8. Exfiltrate or Tamper with Data in Transit from the Genomics Sequencing Laboratory Data Storage to Research Partner</b> <b>MITRE ATT&amp;CK Technique(s):</b> <a href="#">T1565.002 – Data Manipulation: Transmitted Data Manipulation</a>	The data being sent from the Data Delivery DMZ to the Research Partner could be altered during transit, affecting data integrity. This could cause incorrect data to be used in downstream analysis and may even be done for commercial gain. A further risk is that data are not destroyed according to policy after being transferred by the sequencing provider.
<b>9. Spoofing User to Genomics Laboratory Data Storage</b> <b>MITRE ATT&amp;CK Technique(s):</b> <a href="#">T1078 – Valid Accounts</a>	An actor could spoof that they are a trusted party connecting to Globus. Only authorized and authenticated users should be able to access the genomic data at the Genomics Sequencing Laboratory. However, adversaries have used methods to obtain valid credentials to spoof users.
<b>10. Spoofing Researcher to Research Partner Login</b> <b>MITRE ATT&amp;CK Technique(s):</b> <a href="#">T1199 – Trusted Relationship</a> <a href="#">T1078 – Valid Accounts</a>	Research environments need proper authorization and authentication to protect patient consent, safeguard intellectual property, and prevent malware. Common IT behaviors in research environments, such as lack of MFA, sharing default passwords among research groups, multiple users sharing the same computer account, hardcoding passwords, or embedding credentials in software that is then shared into the public domain, are possible mechanisms that malicious actors could use to take advantage of trusted relationships. This TTP is possible through leveraging trusted relationships or obtaining valid credentials.

669 **2.2.3. Attack Trees**

670 Although developing attack trees can require more expertise, they effectively tell the story of  
 671 how threats can be exploited. They can help prioritize mitigations by helping those less skilled  
 672 in cybersecurity understand the risks if mitigations are not implemented. The attack trees for  
 673 this paper incorporated MITRE ATT&CK TTPs to provide details for some of the STRIDE threats  
 674 because MITRE ATT&CK identifies specific threats that have been exploited by known  
 675 adversaries. Attack trees help highlight effective mitigations and show how attacks often  
 676 involve multiple steps and often leverage multiple threats. Attack trees can help identify when  
 677 multiple TTPs are available to accomplish the next step in the attack tree, making the mitigation  
 678 less valuable to the defender than mitigations that have only a single path to reach the next  
 679 node.

680 Attack trees can help an organization understand the impact and likelihood of a cyber incident  
 681 (ID.RA-05; MO:1,3,8) and prioritize threats by incorporating adversarial actions into threat  
 682 modeling. Attacks typically require multiple steps, as documented in MITRE ATT&CK or the

683 [Lockheed Martin Cyber Kill Chain®](#). This section outlines two attack tree examples, one for the  
684 Research Partner and one for the Genomic Sequencing Laboratory.

685 Attack trees incorporate various shapes and connections to provide context to a flow carried  
686 out by a malicious actor. The diagrams are organized in a top-down manner, meaning the top  
687 elements show possible starting points for the attacker to choose from. The bottom of the  
688 diagram identifies the ultimate goal, such as exfiltration of data or denial of service.

689 Squares represent TTPs from the MITRE ATT&CK Matrix that an attacker may leverage to reach  
690 their goal. Arrows leaving the squares indicate moving to the next step. Once a technique has  
691 been completed, the arrow either connects to the next technique or connects to a stadium, the  
692 "or" operator. The squares in the diagrams show areas where multiple TTPs are viable and  
693 where the flow can continue as long as at least one TTP is accomplished.

694 The diamonds contain conditional statements, evaluated as either true or false. If true, flow  
695 continues downward. If false, there may be additional TTPs that need to be carried out before  
696 making progress toward the end goal. The specific branch will be represented by "True" and  
697 "False" on the outward arrows from the diamond. Not all diamonds will have a branch for both  
698 possibilities. Some may only represent a true branch, signifying that the false condition results  
699 in no possible progress or alternatives.

#### 700 **2.2.3.1. Attack Tree 1: Untrusted Software Implanted with Malware**

701 Figure 17 illustrates how untrusted software can be used to conduct a ransomware attack  
702 and/or exfiltrate the genomic data of the Research Partner. Since the untrusted software's code  
703 is outside the analyst's control, preventing adversarial actions will need to take place after the  
704 code has been tainted. Possible mitigations for this attack include detecting that the code has  
705 been tainted or restricting its privileges by sandboxing or containerizing the code during  
706 execution. With these two mitigations in place, the code would have to be both stealthy to  
707 avoid detection and clever enough to detect containerization and escape. After this, the  
708 defender has several additional opportunities that can either prevent the malware from having  
709 the desired effect (such as firewalls that prevent ingress tool transfer or exfiltration of data) or  
710 detect the malware (for example, monitoring for elevation of privilege or encryption behavior)  
711 followed by a robust response to limit the damage. The listed TTPs of each step (Table 6) can be  
712 useful for evaluating whether a tool has coverage of that TTP using third-party coverage tests  
713 such as [MITRE ATT&CK Evaluations](#).




Figure 17. Attack Tree 1: Untrusted Software Implanted with Malware

715


**Table 6. Details for the Attack Tree 1**

<b>Technique ID and Name</b>	<b>Tactic ID and Name</b>	<b>Description</b>
<a href="#">T1587.001</a> Develop Capabilities: Malware	<a href="#">TA0042</a> Resource Development	Attacker develops a new research tool containing malicious code.
<a href="#">T1608.001</a> Stage Capabilities: Upload Malware	<a href="#">TA0042</a> Resource Development	Attacker makes the research tool publicly available for analysts to download and use.
<a href="#">T1195.002</a> Supply Chain Compromise: Compromise Software Supply Chain	<a href="#">TA0001</a> Initial Access	Attacker forks a publicly available research tool and includes malicious code.
<a href="#">T1204</a> User Execution	<a href="#">TA0002</a> Execution	Analyst attempts to use the tool or model file they downloaded.
<a href="#">T1613</a> Container and Resource Discovery	<a href="#">TA0007</a> Discovery	Malicious code checks to determine whether it has been downloaded inside of a container.
<a href="#">T1611</a> Escape to Host	<a href="#">TA0004</a> Privilege Escalation	Malicious code utilizes incorrect container settings to escape and gain access to the host system.
<a href="#">T1068</a> Exploitation for Privilege Escalation	<a href="#">TA0004</a> Privilege Escalation	Malicious code gains additional privileges to attack the host system.
<a href="#">T1005</a> Data from Local System	<a href="#">TA0009</a> Collection	Attacker collects information from the compromised system.
<a href="#">T1567</a> Exfiltration Over Web Service	<a href="#">TA0010</a> Exfiltration	Attacker steals information to be used for blackmailing.
<a href="#">T1018</a> Remote System Discovery	<a href="#">TA0007</a> Discovery	Attacker scans for other systems to find options to move laterally.
<a href="#">T1049</a> System Network Connections Discovery	<a href="#">TA0007</a> Discovery	Attacker scans for network connections to find options to move laterally.
<a href="#">T1105</a> Ingress Tool Transfer	<a href="#">TA0011</a> Command and Control	Attacker installs a backdoor onto the compromised system.
<a href="#">T1486</a> Data Encrypted for Impact	<a href="#">TA0040</a> Impact	Attacker encrypts files on the host.
<a href="#">T1499</a> Endpoint Denial of Service	<a href="#">TA0040</a> Impact	Compromised system experiences denial of service event from the ransomware attack.

716 **2.2.3.2. Attack Tree 2: Using the Genomic Sequencer Remote Access to Deploy Ransomware**  
717 **in Genomic Sequencing Laboratory Datastore**

718 In this example, shown in Figure 18, the Genomic Sequencer is tampered with to gain access to  
719 the Cluster Filesystem in the Genomic Sequencing Laboratory environment. The manufacturer  
720 may have access to the sequencer to conduct updates and monitoring. Spoofing the  
721 manufacturer relationship would give the adversary significant access, not only to the device  
722 but also to other systems that trust the device.

723 This suggests that mitigations used to validate the manufacturer (such as enforcing firewall  
724 rules that only allow access from the manufacturer's servers, monitoring for brute force  
725 attacks, or restricting connections to Transport Layer Security (TLS) 1.3) could stop some of the  
726 attacks. Limiting the trust of the sequencer by the rest of the system could limit the damage of  
727 a sequencer compromise. If the Cluster Filesystem enforces partitioning of data from  
728 sequencers, such that each sequencer can only access its own data, and then only for a limited  
729 time, that could prevent ransomware from affecting the genomic data being stored on that  
730 system. Again, the listed TTPs of each step (Table 7) can be useful for evaluating whether a tool  
731 has coverage of that TTP using third-party coverage tests.



**Figure 18. Attack Tree 2: Using the Genomic Sequencer Remote Access to Deploy Ransomware in the Genomic Sequencing Laboratory Datasore**

732  
733

**Table 7. Details for Attack Tree 2**

Technique ID and Name	Tactic ID and Name	Description
<a href="#">T1195</a> Supply Chain Compromise	<a href="#">TA0001</a> Initial Access	System is compromised prior to being installed in the genomics laboratory.
<a href="#">T1199</a> Trusted Relationship	<a href="#">TA0001</a> Initial Access	Attacker compromises the device manufacturer and gains access.
<a href="#">T1078</a> Valid Accounts	<a href="#">TA0001</a> Initial Access	Attacker knows the credentials used by the manufacturer for remote maintenance.
<a href="#">T1557</a> Adversary-in-the-Middle	<a href="#">TA0006</a> Credential Access	Attacker intercepts network traffic to gain knowledge of the remote maintenance credentials.
<a href="#">T1110</a> Brute Force	<a href="#">TA0006</a> Credential Access	Attacker tries a brute force password attack to gain access to the device.
<a href="#">T1555</a> Credentials from Password Stores	<a href="#">TA0006</a> Credential Access	Attacker uses a well-known password to obtain access to the device.
<a href="#">T1087</a> Account Discovery	<a href="#">TA0007</a> Discovery	Attacker attempts to discover the accounts present on the Sequencer.
<a href="#">T1083</a> File and Directory Discovery	<a href="#">TA0007</a> Discovery	Attacker examines the directories and files present on the Sequencer.
<a href="#">T1049</a> System Network Connections Discovery	<a href="#">TA0007</a> Discovery	Attacker determines the network connectivity of the Sequencer.
<a href="#">T1082</a> System Information Discovery	<a href="#">TA0007</a> Discovery	Attacker tries to learn more about the operating system and services of the Sequencer.
<a href="#">T1602</a> Data from Configuration Repository	<a href="#">TA0009</a> Collection	Attacker collects information about how the Sequencer is configured.
<a href="#">T1105</a> Ingress Tool Transfer	<a href="#">TA0011</a> Command and Control	Attacker transfers a backdoor and additional tools onto the Sequencer.
<a href="#">T1005</a> Data from Local System	<a href="#">TA0009</a> Collection	Attacker collects information from the device/system.
<a href="#">T1554</a> Compromise Host Software Binary	<a href="#">TA0003</a> Persistence	Attacks creates a backdoor on the Sequencer.
<a href="#">T1136.001</a> Create Account: Local Account	<a href="#">TA0003</a> Persistence	Attacker creates a new local account on the Sequencer to allow for persistence.
<a href="#">T1080</a> Taint Shared Content	<a href="#">TA0008</a> Lateral Movement	Attacker alters run data and adds malicious code.
<a href="#">T1021</a> Remote Services	<a href="#">TA0008</a> Lateral Movement	Attacker exploits the connection between the Sequencer and Cluster Filesystem.
<a href="#">T1068</a> Exploitation for Privilege Escalation	<a href="#">TA0004</a> Privilege Escalation	Attacker exploits the Cluster Filesystem to gain escalated privileges.
<a href="#">T1570</a> Lateral Tool Transfer	<a href="#">TA0008</a> Lateral Movement	Attacker moves malicious tools from the Sequencer to the Cluster Filesystem.
<a href="#">T1119</a> Automated Collection	<a href="#">TA0009</a> Collection	Attacker sets up a mechanism to automatically collect run data from the Sequencer.
<a href="#">T1020</a> Automated Exfiltration	<a href="#">TA0010</a> Exfiltration	Attacker sets up a way to automatically exfiltrate the information collected.
<a href="#">T1048</a> Exfiltration Over Alternative Protocol	<a href="#">TA0010</a> Exfiltration	Attacker uses an available medium to exfiltrate the Cluster Filesystem data.
<a href="#">T1567</a> Exfiltration Over Web Service	<a href="#">TA0010</a> Exfiltration	Attacker uses a web service to exfiltrate the Cluster Filesystem data.



735 **2.3. Question 3: What are we going to do about it?**

736 To address Question 3, the *Playbook* describes four strategies [\[9\]](#):

- 737 **1. Eliminate.** This is the most desired outcome; however, it is often challenging and may  
738 involve forgoing a specific feature or functionality. For example, not collecting human  
739 subject health data would eliminate the threat of exfiltration of health data. If that  
740 feature or function is required to accomplish one of the scenario’s Mission Objectives,  
741 then eliminating the threat is not possible.
- 742 **2. Mitigate.** This involves identifying, adding, and/or improving controls to protect, detect,  
743 respond to, or recover from attacks. For example, requiring multifactor authentication  
744 (MFA) instead of only username and password would mitigate (but not eliminate) the  
745 threat of someone spoofing an authorized user.
- 746 **3. Accept.** In any system, there are unmitigated threats that cannot be eliminated or  
747 mitigated whose risk is judged to be acceptable. However, these accepted threats need  
748 to be documented and periodically reviewed, as different organizations have different  
749 risk tolerance levels that may change over time.
- 750 **4. Transfer Responsibility.** This strategy transfers the risk to another entity, who may have  
751 resources of their own to mitigate the threat (for example, requiring users to choose  
752 secure passwords or documenting the risk in an informed consent agreement) or who  
753 are willing to accept the risk.

754 When working on Question 3, it is important to consider all four options: eliminate, mitigate,  
755 accept, and transfer. The impact on the mission posed by the threat, as well as the  
756 organization’s risk tolerance, will guide decision-making. The most common and perhaps most  
757 complex option is to mitigate the threat using one or more mitigations to reduce the residual  
758 risk to an acceptable level. There may be multiple mitigations for a threat with varying costs  
759 and effectiveness. Choices of mitigations should be guided by the organization’s mission,  
760 regulatory or legal requirements, risk tolerance, and resources.

761 Whichever mitigation options are chosen, they need to be documented adequately to be  
762 implementable. If a mitigation is called for, there should be sufficient detail so that the  
763 mitigation can be implemented and tested. Additionally, the remaining residual risk after the  
764 mitigation is implemented should be documented. If a risk is accepted, there needs to be  
765 sufficient documentation to understand the reasoning and assumptions that were used in  
766 deriving that solution because in the future, some of the assumptions may change, including an  
767 organization’s risk tolerance.

768 This section explores mitigations that may address threats to genomic data, keeping in view the  
769 large data size, the need for secure sharing, and research environment requirements. The  
770 following list of mitigations, while not exhaustive, highlights key mitigations that emerged from  
771 the threat modeling exercise. A unique identifier for each mitigation was assigned to assist with  
772 documentation and traceability efforts. Identifiers for the Genomic Sequencing Laboratory  
773 (Lab) start with “L” while identifiers for the Research Partner (Partner) start with “P.”

774 Table 8. Example Mitigation Table summarizes the mitigations detailed in the following  
775 sections. The table identifies the section number that describes the mitigation, the short title

776 for the mitigation and unique mitigation identifier (ID), the responsible party (Owner), the  
777 corresponding key threat number (from [Section 2.2.2](#)), the related attack tree (1 or 2), and the  
778 list of prioritized CSF Profile Subcategories along with applicable Mission Objectives (MO 1, 3, or  
779 8 from Table 1).

780 In selecting and implementing mitigations, it is important to consider ownership,  
781 maintainability, verifiability (preferably automated), and usability. All systems will inevitably  
782 need updates and modifications. The responsible party (Owner) for maintenance and  
783 verification of each mitigation needs to be clearly defined. Mitigations should be verified after  
784 these changes to confirm that they still provide the expected utility. Systems can be monitored  
785 with appropriate logging and ongoing testing to identify any issues.

786 **Table 8. Example Mitigation Table**

Section & Short Title (Unique ID)	Owner (Example)	ATT&CK Mitigation(s) ID and Name	Key Threat Number	Attack Tree	CSF Profile Subcategory and Mission Objective
2.3.1 Broker Access (L1)	Lab IT	<a href="#">M1029</a> – Remote Data Storage <a href="#">M1030</a> – Network Segmentation <a href="#">M1035</a> – Limit Access to Resource Over Network			(PR.DS-01; MO:1,3,8) (PR.DS-02; MO:1,3,8)
2.3.2 Use Network Isolation and Firewalls (L2)	Lab IT	<a href="#">M1016</a> – Vulnerability Scanning <a href="#">M1021</a> – Restrict Web-Based content <a href="#">M1030</a> – Network Segmentation <a href="#">M1037</a> – Filter Network Traffic <a href="#">M1031</a> – Network Intrusion Prevention		1	(ID.RA-02; MO:3) (PR.DS-01; MO:8) (PR.IR-01; MO:1,8)
2.3.2 Use Network Isolation and Firewalls (P2)	Partner IT	<a href="#">M1016</a> – Vulnerability Scanning <a href="#">M1021</a> – Restrict Web-Based content <a href="#">M1030</a> – Network Segmentation <a href="#">M1037</a> – Filter Network Traffic <a href="#">M1031</a> – Network Intrusion Prevention	6, 7	1	(ID.RA-02; MO:3) (PR.DS-01; MO:8) (PR.IR-01; MO:1,8)
2.3.2.1 Segment Network (L3)	Lab IT	<a href="#">M1030</a> – Network Segmentation	4	1	(PR.AA-05; MO:1)
2.3.2.2 Firewall the Sequencer (L4)	Lab IT	<a href="#">M1035</a> – Limit Access to Resource Over Network <a href="#">M1037</a> – Filter Network Traffic	1, 3	1	(PR.DS-01; MO:8) (PR.DS-10; MO:1,8)
2.3.2.3 Firewall the Cluster Filesystem (L5)	Lab IT and/or Cluster Filesystem Admin (shared)	<a href="#">M1035</a> – Limit Access to Resource Over Network <a href="#">M1037</a> – Filter Network Traffic		1	(PR.DS-01; MO:8) (PR.DS-10; MO:1,8)
2.3.2.4 Firewall the DMZ (L6)	Lab IT	<a href="#">M1035</a> – Limit Access to Resource Over Network <a href="#">M1037</a> – Filter Network Traffic			(PR.DS-01; MO:8)

Section & Short Title (Unique ID)	Owner (Example)	ATT&CK Mitigation(s) ID and Name	Key Threat Number	Attack Tree	CSF Profile Subcategory and Mission Objective
2.3.3 Use RBAC on the Cluster Filesystem (L7)	Cluster Filesystem Admin	<a href="#">M1018</a> – User Account Management <a href="#">M1022</a> – Restrict File and Directory Permissions	2	2	(PR.DS-01; MO:8) (PR.DS-10; MO:1,8)
2.3.4 Authorize and Authenticate (L8)	Lab HR for Authorize; IT for Authenticate	<a href="#">M1018</a> – User Account Management <a href="#">M1027</a> – Password Policies <a href="#">M1032</a> – Multi-factor Authentication <a href="#">M1036</a> – Account Use Policies	1, 4, 9	2	(GV.SC-02; MO:1,3,8) (PR.AA-01; MO:1,3) (PR.AA-03; MO:8) (PR.AA-05; MO:1,3)
2.3.4 Authorize and Authenticate (P3)	Partner Principal Investigator for Authorize; IT for Authenticate	<a href="#">M1018</a> – User Account Management <a href="#">M1027</a> – Password Policies <a href="#">M1032</a> – Multi-factor Authentication <a href="#">M1036</a> – Account Use Policies	6, 9, 10		(PR.AA-01; MO:1,3) (PR.AA-03; MO:8) (PR.AA-05; MO:1,3)
2.3.5 Restrict Physical Access (L9)	Lab Security	N/A – ATT&CK does not cover physical mitigations	1, 3, 4	2	(PR.AA-06; MO:8)
2.3.6 Implement Data Retention Policies (L10)	Lab Legal and Cluster Filesystem Admin	<a href="#">M1057</a> – Data Loss Prevention	2	2	(GV.OC-03; MO:1,3,8) (ID.AM-08; MO:1,8)
2.3.7 Conduct Backups (L11)	Admin for Cluster Filesystem; IT for Other Systems	<a href="#">M1053</a> – Data Backup	2		(PR.DS-11; MO:1) (PR.DS-01; MO:1,8)
2.3.7 Conduct Backups (P4)	Bioinformaticist	<a href="#">M1053</a> – Data Backup	5, 6	1	(PR.DS-11; MO:1) (PR.DS-01; MO:1,8)
2.3.8 Containerize Untrusted Software (P5)	Bioinformaticist	<a href="#">M1048</a> – Application Isolation and Sandboxing	5, 7	1	(DE.CM-09; MO:1,3,8)
2.3.9 Implement Least Functionality (L12)	Lab IT	<a href="#">M1033</a> – Limit Application Installation <a href="#">M1042</a> – Disable or Remove Feature or Program <a href="#">M1045</a> – Code signing <a href="#">M1051</a> – Update Software	2	2	(ID.AM-08; MO:1,3,8) (ID.RA-01; MO:3) (PR.AA-05; MO:1,3,8) (PR.PS-01; MO:1,3) (PR.PS-02; MO:1,3,8)
2.3.9 Implement Least Functionality (P6)	Bioinformaticist	<a href="#">M1033</a> – Limit Application Installation <a href="#">M1042</a> – Disable or Remove Feature or Program <a href="#">M1045</a> – Code signing <a href="#">M1051</a> – Update Software	5, 6	1	(ID.AM-08; MO:1,3,8) (ID.RA-01; MO:3) (PR.AA-05; MO:1,3,8) (PR.PS-01; MO:1,3) (PR.PS-02; MO:1,3,8)

Section & Short Title (Unique ID)	Owner (Example)	ATT&CK Mitigation(s) ID and Name	Key Threat Number	Attack Tree	CSF Profile Subcategory and Mission Objective
2.3.10 Encrypt Data (L13)	Lab IT and Cluster Filesystem Owner (Shared)	<a href="#">M1041</a> – Encrypt Sensitive Data	2, 3	2	(PR.DS-01; MO:1,3,8) (PR.DS-02; MO:1,3,8)
2.3.10 Encrypt Data (P7)	Bioinformaticist and Researcher (Shared)	<a href="#">M1041</a> – Encrypt Sensitive Data	5, 6, 7, 8	1	(PR.DS-01; MO:1,3,8) (PR.DS-02; MO:1,3,8)

787 **2.3.1. Broker Access to Genomic Data**

788 Organizations sharing genomic data may use an intermediary to provide protection between  
789 the internet and the Genomics Sequencing Laboratory datastore. A secure system that is  
790 hardened yet performant for transferring very large datasets is likely to meet these  
791 organizational needs. Setting up Globus in a Data Delivery DMZ can perform this intermediary  
792 function. A peer-reviewed design pattern for Globus setup is available at PeerJ Computer  
793 Science [\[16\]](#), though other implementations could also suffice. Key features the solution can  
794 provide include creating an intermediary between the untrusted internet and the storage  
795 system, enforcing strong authentication, encrypting data in transit, logging all access, and  
796 offering high performance.

797 **2.3.2. Use Network Isolation and Firewalls**

798 A target configuration for all firewalls used on the perimeter and within the environment is to  
799 deny all traffic by default and only allow the sources, targets, ports, and protocols required for  
800 functionality by the manufacturers or custom interconnectivity between networks. Specific  
801 protocols and destinations allowed include those needed for filesystem mounts, remote  
802 maintenance, vendor monitoring, software updates, and internal monitoring.

803 Details on how to properly secure the network are provided in NIST SP 800-215 [\[17\]](#). Across all  
804 mitigations, configuration of firewalls, Domain Name System (DNS), and Network Time Protocol  
805 (NTP) should follow these recommended practices:

- 806 • Firewalls should use external dynamic lists (EDLs) that block known malicious sites  
807 before allowing exceptions.<sup>7</sup> These EDLs need to be configured to update automatically  
808 (e.g., daily) since threats are constantly evolving. An organization may also choose to  
809 block all access from locations of concern.
- 810 • DNS should conform to guidance on Protective DNS if available, as recommended by the  
811 National Security Agency (NSA) and the Cybersecurity & Infrastructure Security Agency

<sup>7</sup> Example EDLs are available at <https://docs.paloaltonetworks.com/pan-os/10-1/pan-os-admin/policy/use-an-external-dynamic-list-in-policy/built-in-edls> and <https://rules.emergingthreats.net/>.

812 (CISA) [\[18\]](#). If that option is not available or considered too costly to implement, DNS  
813 can use free alternatives such as Quad9, OpenDNS, or Google Public DNS that provide  
814 blocking for known malicious domains.

- 815 • NTP should only allow for an internal time server and use only approved time services,  
816 such as [NIST's Official U.S. time service](#) or similarly trusted time service.

817 The subsections below describe mitigations, including network segmentation and specific  
818 exceptions needed for the firewalls that protect the Genomic Sequencer and the Cluster  
819 Filesystem. Some of the devices, such as the Genomic Sequencer, Cluster Filesystem, and  
820 servers, may include firewalls. These firewalls can provide defense in depth and can be  
821 activated and configured to limit traffic, though this is not a substitute for more sophisticated  
822 firewalls with EDLs along with advanced capabilities at the perimeter. Advanced firewall  
823 capabilities can provide perimeter protection, threat prevention, and network analysis of lab  
824 instrumentation, Internet of Things (IoT) devices, and security enclave infrastructure.

825 The applications and services within the Management and Tooling environment could include  
826 several passive and active security tools to protect the research and laboratory environments.  
827 Vulnerability scanning can be performed on a scheduled and *ad hoc* basis to detect security  
828 flaws in underlying hardware and software within the security enclave. Behavioral analysis and  
829 threat detection could be performed on the logged ingress and egress network traffic within  
830 the secure enclave. Network intrusion detection sensors could provide real-time alerting of  
831 suspicious activity within the enclave. In addition, all network traffic in the enclave could be  
832 recorded and retained for a designated period to enable in-depth analysis of device and user  
833 activities.

#### 834 **2.3.2.1. Network Segmentation**

835 Different sections of the Genomic Sequencing Laboratory can be segmented from each other  
836 using virtual local area networks (VLANs). At minimum, the Wet Lab, the Research  
837 Environment, the Data Delivery DMZ, and the Management and Tooling environments are  
838 expected to be separate zones. These zones are ideally segregated on different networks or  
839 virtual networks with explicit, limited access between the zones using access control lists  
840 (ACLs). Data traveling between zones can use the most recent version of TLS (e.g., TLS 1.3).

841 Trust boundaries like the Research Computing Environment, hosting environment, and Data  
842 Delivery DMZ are VLANs that are segregated from other environments and the outside world.  
843 Laboratories and sequencing networks have explicit permissions that allow them to connect  
844 and execute genomic pipelines in the security enclave. This is accomplished by segmenting  
845 VLANs, implementing ACLs, and using network isolation tools and firewall practices mentioned  
846 in the previous section.

#### 847 **2.3.2.2. Firewalls for the Genomic Sequencer**

848 Firewalls on and around the Genomic Sequencer (such as its attached workstation) can be  
849 configured to deny-all traffic by default, allowing only the ports and protocols required by the

850 manufacturer to protect from threats like those described in [Section 2.2.2](#) and attack tree 2  
851 (Figure 18). Specific protocols and destinations that can be allowed include access to the Cluster  
852 Filesystem mounts, remote maintenance, vendor monitoring, software updates, and internal  
853 monitoring. Organizations can follow manufacturer guidance on allowed network connections.  
854 For example, Table 9 lists the endpoints for ingress and/or egress to support the Illumina  
855 sequencer<sup>8</sup>, sorted by geographic region.

856 **Table 9. Illumina ACLs**

▶ US East (N. Virginia)

2. Identify the endpoints for your instrument.

Each instrument includes specific endpoints that are categorized as either required, recommended, or optional. These endpoints are used for the following purposes:

- Authorizing certificates
- Displaying fonts
- Telemetry
- Accessing Illumina support material
- Sending IDAT files or data to ICA

▼ iScan

The following table shows the applicable endpoints for the iScan.

Endpoint	Category	Purpose
ica.illumina.com	Required	Send IDAT files to ICA
o.es2.us	Required	Certificate authorization
ocsp.digicert.com	Required	Certificate authorization
ocsp.pki.goog/gcr2	Required	Certificate authorization
ocsp.rootca1.amazontrust.com	Required	Certificate authorization
ocsp.rootg2.amazontrust.com	Required	Certificate authorization
ocsp.sca1b.amazontrust.com	Required	Certificate authorization
fonts.gstatic.com	Required	Display fonts
fonts.googleapis.com	Recommended	Display fonts
cdn.walkme.com	Recommended	Telemetry
cdn3.userzoom.com	Recommended	Telemetry
dpm.demdex.net	Recommended	Telemetry
illuminainc.demdex.net	Recommended	Telemetry
illuminainc.tt.omtrdc.net	Recommended	Telemetry
smetrics.illumina.com	Recommended	Telemetry
google.com	Recommended	Telemetry
google-analytics.com	Recommended	Telemetry
stats.g.doubleclick.net	Recommended	Telemetry
illumina.com	Optional	Access Illumina support material

857 Table 10 provides another example of the PacBio Sequencer ACLs [\[19\]\[20\]](#). Additional  
858 information is available at their support site, including preparation documentation for ports and  
859 firewalls.

<sup>8</sup> More information available at: <https://support-docs.illumina.com/SHARE/NetworkSecurity/Content/SHARE/NetworkSecurity/ControlComputerFirewall.htm>.

860

**Table 10. PacBio Sequencer ACLs**

Source	Destination	Port/Protocol	Description
Revio Instrument Control Computer (ICC)	SecureLink Servers	443/tcp	Communication for remote support (PacBio Insight)
ICC	Data Transfer Server	22/tcp, 873/tcp, or 80/tcp and 443/tcp depending on protocol	Data transfer from instrument to customer storage
ICC	Customer or external NTP servers	123/udp	Used for updating machine time. Defaults to pool.ntp.org
ICC	Customer server	53/udp or 53/tcp	Nameservers
ICC	SMRT Link server	8243/tcp	Communication from instrument to SMRT Link
SMRT Link server	ICC	9243/tcp	Communication from SMRT Link to instrument
Customer laptop/desktop PC	SMRT Link server	9090/tcp	SMRT Link GUI http
Customer laptop/desktop PC and ICC	SMRT Link server	8243/tcp	SMRT Link web services and GUI https
Customer laptop/desktop PC	SMRT Link server	9443/tcp	SMRT Link Administration https (API Management Interface)
SMRT Link server	Shared Network File System (NFS) storage	NFS ports (may vary depending on configuration)	NFS shared storage access shared data to analyze
SMRT Link server	PacBio Event server ( <a href="https://smrtlink-eve.pacbccloud.com:8083">https://smrtlink-eve.pacbccloud.com:8083</a> )	8083/tcp	Optional reporting of server metrics to PacBio Tech Support
SMRT Link server	PacBio Update server ( <a href="https://smrtlink-update.pacbccloud.com:8084">https://smrtlink-update.pacbccloud.com:8084</a> )	8084/tcp	Downloading Chemistry Updates
HPC nodes	Shared NFS storage	NFS ports 2049/tcp (ports vary depending on configuration)	NFS shared storage access shared data to analyze

861 Generally, the sequencer will communicate with a Cluster Filesystem or other storage using  
 862 industry-standard mount protocols like Network File System (NFS) and Server Message Block  
 863 (SMB) along with varying types of storage from block, object, or database access, all with their  
 864 necessary ports and protocols. Additional ports and protocols may be required to allow the  
 865 sequencer to access the internet for updates and vendor support. These ports and protocols  
 866 need to be allowed, with proper restrictions in place for specific source and destination  
 867 addresses.

### 868 2.3.2.3. Firewalls for the Cluster Filesystem

869 Cluster Filesystem firewalls can also be configured with a default deny-all rule, allowing only the  
 870 ports and protocols required by the Cluster Filesystem (e.g., Globus, sequencers, researchers in  
 871 the zone). Generally, a Cluster Filesystem will also support industry-standard mount protocols  
 872 like NFS and SMB along with varying types of storage from block, object, or database access, all  
 873 with their necessary ports and protocols. Refer to manufacturer guidance for more details.


#### 874 2.3.2.4. Firewalls for the Data Delivery DMZ

875 Data Delivery DMZ firewalls can be configured appropriately to mitigate the significant risks  
876 from outside connections. Advanced firewall capabilities can be leveraged to protect perimeter  
877 networks and internal network traffic connecting trust boundaries. Capabilities that can be  
878 enabled include advanced firewall functions such as packet filters and network address  
879 translation, stateful inspection, deep packet inspection, threat prevention, audit and logging,  
880 and access control.

881 The Data Delivery DMZ will require access to ports 80, 443, 4443, 50000, and 51000 inbound  
882 from ANY and from those same ports outbound to ANY (note, [Section 2.3.2](#) EDL rules need to  
883 be executed before this exception, will deny connections from known malicious IP addresses,  
884 and can be configured to also block IPs from locations of concern). Ports 50000 to 51000 are  
885 used for GridFTP data channel traffic and used only during transfers as needed; the data  
886 channel traffic is sent directly between endpoints and not the Globus service. Port 443 inbound  
887 is used by the manager service, GridFTP control channel traffic, and Hypertext Transfer Protocol  
888 Secure (HTTPS) access to collections. Port 443 outbound is used to communicate with cloud  
889 storage services, pull Globus Connect Server packages from the Globus repository, and  
890 communicate with the Globus service through its representational state transfer (REST)  
891 application programming interface (API).

#### 892 2.3.3. Use RBAC on the Cluster Filesystem

893 Organizations will benefit from the maintenance and enforcement of ACLs across all internal  
894 networks, leveraging role-based access control (RBAC). This includes all connections requiring  
895 X.509 certificates to be permitted for internal IP addresses only. Access to the management  
896 APIs or web console should be validated against either an external Lightweight Directory Access  
897 Protocol (LDAP), Active Directory, or OpenStack Keystone data and allowed only with MFA. The  
898 Cluster Filesystem in the Research Computing environment can encrypt data at rest and in  
899 transit. Figure 19 shows an example of client certificates that can also be used to limit access  
900 for specific roles to only allow read-only or limit privileged access. RBAC can limit sequencer  
901 access to a specific directory, separate from other sequencers and data that have been quality  
902 controlled.



903

Figure 19. Certificate Example



#### 904 **2.3.4. Authenticate and Authorize All Users**

905 Enforcing authentication and authorization will reduce risk to all environments for both the  
906 Research Partner and Genomic Sequencing Laboratory. This can be done by requiring unique  
907 users, promptly revoking credentials of users that depart an organization, RBAC, strong  
908 passwords, lockout on too many failed login attempts, and MFA. Local and remote user access  
909 can be controlled using a combination of LDAP, Kerberos, Single Sign-On (SSO), and network  
910 ACLs. These systems limit and control access to the security enclave, specific systems, and  
911 volumes based on the user's role. Remote users, including genomic and cybersecurity  
912 providers, can connect to the security enclave using their unique credentials, MFA, and a virtual  
913 private network (VPN such as Global Protect) client. Organizations can implement MFA with an  
914 authenticator service such as Google Authenticator, Duo Authenticator, 2FAS<sup>9</sup>, or RSA  
915 Authenticator.

916 There will be cases where, for some users, the authentication and authorization responsibilities  
917 are transferred. For example, the Genomic Sequencing Laboratory may require the Research  
918 Partner to enforce the authentication and authorization requirements for the users that will  
919 have access to the Research Partner's data in the Cluster Filesystem. The transfer of that  
920 responsibility needs to be communicated from the Genomic Sequencing Laboratory to the  
921 Research Partner.

#### 922 **2.3.5. Restrict Physical Access to Environments**

923 Facilities hosting research computing and hosting environments can benefit from performing a  
924 risk assessment to determine the layers of physical security needed to protect personnel,  
925 assets, and data. The risk assessment may lead to recommending the following mitigations:

- 926 • Security personnel to check identity badges along with access-control doors for rooms  
927 where servers are located
- 928 • All points of ingress and egress to be controlled using automatically locking doors  
929 equipped with key card readers, supplemented by a 24/7 security guard presence and  
930 surveillance cameras
- 931 • Access to more sensitive areas like the data centers and cabinets to be controlled via  
932 key cards, multi-factor passcodes, and mantraps to restrict access to only those with a  
933 legitimate business need
- 934 • Additional video surveillance, fencing, and physical security protections may also be  
935 needed around the facilities
- 936 • Prompt revocation of physical access for users who leave the organization

#### 937 **2.3.6. Implement Data Retention Policies for the Genomic Data**

938 Data retention policies for organizations processing genomic data will vary based on contractual  
939 and regulatory requirements. Contractual requirements should be straightforward, written into

---

<sup>9</sup> 2FAS is an open-source two-factor authentication (2FA) tool.

940 formal agreements, and regularly updated. Regulatory requirements can be more complicated.  
 941 The source of the data may impact the retention requirements. For example, human genomic  
 942 data will fall under different regulations than non-human genomic data, such as privacy and  
 943 consent requirements. The intended use of the data may also impact retention requirements.  
 944 Data collected for research purposes will have different requirements than data collected in a  
 945 clinical context for use in treatment or diagnosis. Once the retention period has elapsed,  
 946 genomic data can be deleted or moved to offline storage to limit liability and prevent  
 947 exfiltration, depending on contractual and regulatory requirements. Care should be taken with  
 948 any remaining physical samples, which may need to be destroyed or returned to the Research  
 949 Partner.

950 **2.3.7. Conduct Backups of Datastores**

951 A variety of backup options are available for sequencing data at both the Research Partner and  
 952 the Genomic Sequencing Laboratory. These range from keeping DNA in the freezer to re-  
 953 sequence when needed to back up sequencing files in a variety of genomic data formats.  
 954 Examples of backup formats include the file format for sequence reads with quality score  
 955 (FASTQ), Binary Alignment/Map (BAM), and Compressed Reference-oriented Alignment Map  
 956 (CRAM).

957 Table 11 details examples of backup options, provides encryption times, and estimates storage  
 958 costs per year for an offsite cloud backup as calculated at the time of this document (2024). For  
 959 Table 11, file sizes are in gigabytes (GB), times are in minutes (m) and seconds (s), and cloud  
 960 storage uses Amazon Web Services (AWS) S3 Deep Glacier Flexible Retrieval.

961 An important aspect of backing up genomic sequencing data is the ability to recover to the last  
 962 known good state, as each file storage option will restore to a different analysis state. A  
 963 genomic analyst will need to identify where in the genomic data lifecycle their analysis or  
 964 responsibilities exist to determine the appropriate backup option. Periodic validation for  
 965 functional backup checks could include re-mapping or variant calling retrieved backup data,  
 966 depending on an organization’s need upon recovery of backups.

967 **Table 11. Genomic Sequencing Backup Options**

<b>Backup Option</b>	<b>File Size (GB) for 30x Human Genome on Illumina NovaSeq</b>	<b>Encryption Time</b>	<b>Notes on “Last Known Good State”</b>	<b>Cost per Year for Secondary Backup in AWS S3 Deep Glacier Flexible Retrieval</b>
DNA in Freezer – sequence as needed	N/A	N/A	Pros – researcher might get to sequence on new technology Cons – cost is likely higher than data backup, not applicable for limited material	Freezer maintenance costs likely amortized over samples and other research projects

Backup Option	File Size (GB) for 30x Human Genome on Illumina NovaSeq	Encryption Time	Notes on “Last Known Good State”	Cost per Year for Secondary Backup in AWS S3 Deep Glacier Flexible Retrieval
FASTQ.GZ (compressed reads file)	2 Files Reads 1 – 24GB Reads 2 – 25GB	Reads 1 – real 14m15.653s Reads 2 – real 16m15.559s	Requires re-mapping of reads that may be expensive if needed to perform for many samples	\$2.12
BAM (mapped reads file)	37GB	real 22m30.975s user 1m11.776s sys 1m27.350s	May be the easiest to work from, but it locks a user into a reference genome and could require extra work	\$1.60
CRAM (compressed mapped reads file)	14GB	real 8m8.965s user 0m25.891s sys 0m28.499s	Not as many analysis tools use a CRAM file as input compared to a BAM, so the user will need to know the impact on their pipeline	\$0.60

968 **2.3.8. Containerize Untrusted Software**

969 A mitigation to the threat from untrusted bioinformatics software is to run this software in  
970 containers with restricted privileges and access. Damage from implanted malware  
971 surreptitiously included in open-source analysis packages can be limited by using hosts and  
972 containers employing a mandatory access control system, whereby process access is controlled  
973 by the system. For example, AppArmor can be used within containers to limit the access of  
974 running processes, restricting what files they are allowed to access and what types of actions  
975 they may perform on these files. Judicious configuration of AppArmor profiles can restrict  
976 which files a process may execute, mitigating or eliminating the impact of implanted malware.

977 **2.3.9. Implement Least Functionality and use Configuration Benchmarks**

978 Benchmarks and least functionality are best practices that can be enforced across all  
979 environments. Least functionality will help eliminate potential risks resulting from running  
980 unneeded services that may be leveraged by adversaries. Organizations can use configuration  
981 benchmarks such as the Defense Information Systems Agency (DISA) Security Technical  
982 Implementation Guides (STIGs) or Center for Internet Security (CIS) Benchmarks when available  
983 for each component of the network. If manufacturers provide configuration benchmarks or  
984 guidance, these can also be enforced. This mitigates the threats from unneeded remote  
985 services running on the system, as described in STRIDE Threat 6 in [Section 2.2.2](#). To maintain  
986 software, teams can enable automatic security updates and scan regularly, remediating  
987 discovered vulnerabilities as described in the *Genomic Data Profile* Subcategories (ID.RA-01;  
988 MO:3).

989 **2.3.10. Encrypt Data Whenever Possible**


990 One of the most effective ways to protect data is encryption. The CSF includes Subcategories  
991 for protecting data at rest and in transit (PR.DS-01, PR.DS-02; MO:1,8).

992 Encryption at rest is accomplished via command line by executing “\$openssl enc  
993 AES128-CBC” on the server before sending the data to secondary storage in a cloud bucket  
994 [21]. Wall clock encryption times using OpenSSL with these parameters range from 16 minutes  
995 and 15 seconds for a 25GB FASTQ.GZ reads file to 8 minutes and 9 seconds for a 14GB CRAM  
996 compressed alignment file.

997 Encryption of data-in-transit between the Genomics Sequencing Laboratory and the Research  
998 Partner is accomplished using the Globus "encrypt transfer" option.

999 When transferring data between two endpoints using Globus, a “data channel” is established  
1000 directly between the source and destination endpoints. The data channel is inaccessible to the  
1001 Globus service but can be accessed by the servers running the endpoints. Users initiating the  
1002 transfer can choose to encrypt the data channel, or the endpoint administrator can enforce the  
1003 encryption of all transfers to or from an endpoint. The specific cipher used for a transfer is  
1004 negotiated between the source and destination endpoints based on their preference-ordered  
1005 list of OpenSSL ciphers (default HIGH). Additionally, Globus employs a TLS-encrypted “control  
1006 channel” to communicate with the source and destination endpoints during transfers.

1007 Many Cluster Filesystems will support encryption in transit to endpoints using client  
1008 certification permissions like those shown in Figure 20 [22], encrypting and limiting access to  
1009 the Filesystem to end users and specific systems.



	Fingerprint	Last seen on host	Last seen	Permissions
<input type="checkbox"/>	aa26043e84c2657c4c85049a6c...	10.0.0.0	7d ago	Tenant Security Group
<input type="checkbox"/>	65459b7daea97fc7cc19590ff23...	10.0.0.0	37d ago	Tenant Security Group
<input type="checkbox"/>	7c3d4a16ee634063c7a3a68a2b...	10.0.0.0	21d ago	Tenant Security Group
<input type="checkbox"/>	7e40aed76d7c5092567dba079...	10.0.0.0	1h ago	Tenant Security Group

1010 **Figure 20. Client Certificate Permission List of a Cluster Filesystem**

1011 **2.4. Question 4: Did we do a good job?**

1012 Question 4, “Did we do a good job?” directs the team to evaluate the effectiveness of answers  
1013 to Questions 1–3. This paper outlines the efforts to document the genomic data processing  
1014 environments (Question 1), identify threats (Question 2), and implement mitigations (Question  
1015 3). The threat modeling process is designed to be iterative. This paper does not attempt to be

1016 comprehensive, but rather to demonstrate the process so that other teams can leverage this  
1017 work to conduct their own threat modeling. Question 4 helps emphasize that this process will  
1018 be repeated to address changes in the system and threat environments.

1019 This section is designed to describe a concrete example of how to address the question, “Did  
1020 we do a good job?” and provide additional activities that can be used by teams to evaluate their  
1021 efforts. All documentation should be easy to update and reviewed periodically to address new  
1022 vulnerabilities, system changes, new assumptions, and changes in risk tolerance.

#### 1023 **2.4.1. Did we do a good job documenting the system and data architecture?**

1024 [Section 2.1](#) documents DFDs and HVDs that deserve special attention in consideration of  
1025 threats against and mitigations of the threats due to their nature of crossing trust boundaries  
1026 and/or affecting critical systems. To provide examples for this process, several of the identified  
1027 HVDs were modeled in more detail with cross-functional diagrams.

1028 The following activities could be used to improve the documentation of the system and data  
1029 architecture:

- 1030 • Analyze HVDs that have not been documented.
- 1031 • Review documentation and information from suppliers, developers, and users to  
1032 consider any updates required.
- 1033 • Review change control processes to ensure that new devices are captured and other  
1034 changes are documented properly.
- 1035 • Review personnel onboarding and offboarding processes.
- 1036 • Review network segmentation and firewall configurations to ensure compliance with  
1037 best practices.
- 1038 • Update the documentation to reflect changes to the threat or system environment,  
1039 including system interconnections, devices added, configurations, access controls, or  
1040 issues identified through testing or monitoring.

1041 The following additional questions help evaluate “Did we do a good job?” answering Question  
1042 1, “What are we working on?”

- 1043 • Is the DFD sufficiently detailed to capture communications between systems,  
1044 particularly those that cross trust boundaries?
- 1045 • Are all communications that cross trust boundaries included?
- 1046 • Have HVDs been highlighted and is there sufficient model detail (such as cross-  
1047 functional, state, and swim lane diagrams) to understand threats against them?
- 1048 • Does the threat modeling explain how HVDs work and assess the impact of threats and  
1049 mitigations on them? Are the diagram details sufficient, or is additional information  
1050 needed from suppliers, developers, or users?

- 1051 • Are the DFD’s trust boundaries accurate? Can they be enforced (for example, by  
1052 network segmentation)?
- 1053 • Is there a justification for every “allow” network firewall rule from a device? For  
1054 Question 1, this is not to evaluate the mitigation but to be sure that you have mapped  
1055 all the dataflows.
- 1056 • Is there a trust boundary for every control mechanism (such as firewall, ACL, lock, or  
1057 login)? Where there is a control mechanism, it likely represents a trust boundary.

#### 1058 **2.4.2. Did we do a good job identifying and documenting threats?**

1059 To answer, “Did we do a good job?” on Question 2, “What could go wrong?” the project team  
1060 evaluates whether the threat model adequately identifies and documents threats to the  
1061 system. [Section 2.2](#) enumerates the threats identified from the STRIDE analysis and the attack  
1062 trees. The team created a table of threats with unique identifiers and selected “key” threats for  
1063 further analysis and specific mitigations. The team highlighted high-value resources such as the  
1064 genomic datastores and the sequencer to focus initial threat identification efforts. The team  
1065 reviewed the STRIDE Element chart and the attack trees to consider gaps in the initial threat  
1066 identification process.

1067 The following actions could improve threat identification:

- 1068 • Review organizational policies, strategies, and processes to determine if there are other  
1069 threat areas not being addressed by the technical evaluation.
- 1070 • Address additional missing STRIDE Elements based on Table 12.
- 1071 • Develop additional attack trees to address broader threat scenarios.
- 1072 • Review published threats and actual cyber incidents identified that are targeted toward  
1073 genomic data to verify they are included in the project’s threat table or attack trees.
- 1074 • Incorporate privacy threat modeling to address potential genomic data privacy  
1075 concerns.

1076 The following additional actions help evaluate “Did we do a good job?” answering Question 2,  
1077 “What could go wrong?”

1078 **Evaluate the comprehensiveness of the STRIDE analysis.** The STRIDE methodology has an  
1079 effective completeness check that uses the STRIDE per element mapping shown in Table 12.<sup>10</sup>  
1080 With this table, a completeness check can be done for the typical threats against external  
1081 entities, processes, datastores, and dataflows. The “X” in Table 12 indicates what threats should  
1082 be present, while the absence of an “X” indicates threats that are not considered and a “?”  
1083 indicates that it depends on the details whether it could be present. For example, in STRIDE,  
1084 Tamper threats against an external entity are not considered because they are outside the  
1085 scope of the organization’s knowledge and control (see the *Playbook* [\[9\]](#) for details).

---

<sup>10</sup> Reproduced from the *Playbook* [\[9\]](#).

1086

**Table 12. STRIDE per Element**

<i>Element</i>	<i>Spoof</i>	<i>Tamper</i>	<i>Repudiate</i>	<i>Info Disclosure</i>	<i>DoS</i>	<i>EoP</i>
<i>External Entity</i>	X		X			
<i>Process</i>	X	X	X	X	X	X
<i>Data Store</i>		X	?	X	X	
<i>Dataflow</i>		X		X	X	

1087 If there are expected threats that have not been considered by the team, the absence of  
 1088 information on that element in the system’s threat table highlights an area for additional  
 1089 consideration. For example, if a repudiation threat against an external entity is not identified in  
 1090 the threat table, that would indicate a gap. Threats against HVDs should be revisited to  
 1091 determine if additional review is necessary or if applying more than one method (e.g., STRIDE  
 1092 and an attack tree) may be helpful.

1093 **Evaluate the comprehensiveness of the attack trees.** When evaluating attack tree  
 1094 documentation:

- 1095 • Consider attacks that have occurred in the genomic stakeholder community and closely  
 1096 adjacent industries. Threat intelligence can be used to identify TTPs favored by actors  
 1097 who are known to target an industry.
- 1098 • Consider whether the attack trees reflect these attacks, or if additional attack trees  
 1099 should be developed.
- 1100 • Consider known vulnerabilities in software and services being used.
- 1101 • Determine whether the threats being considered map to the threats listed in published  
 1102 documents for the genomic community, such as NIST IR 8432 [\[3\]](#).
- 1103 • If the system is operational, consider if past downtime can be mapped to threats  
 1104 identified in the threat model.

1105 **2.4.3. Did we do a good job mitigating the threats?**

1106 [Section 2.3](#) documents the mitigations considered as part of this threat model. Specifically, the  
 1107 team focused on ten “key” mitigations that addressed numerous threats identified, tailoring  
 1108 them to the genomics data sequencing workflow use case. Table 8 maps these key mitigations  
 1109 to the key STRIDE threats identified, the two attack trees, and CSF Subcategories prioritized  
 1110 from the *Genomic Data Profile*.

1111 The following actions could evaluate and improve on these initial mitigations:

- 1112 • Review the mitigations to assess how well they address the key threats identified from  
 1113 STRIDE and the two attack trees.
- 1114 • Expand mitigations to cover additional CSF Subcategories (such as Govern, Respond, and  
 1115 Recover) from the *Genomic Data Profile* that may not be captured in the initial threat  
 1116 model analysis.

- 1117 • Review the documentation from Question 1 to ensure that all mitigations are included.
- 1118 • Review any changes made to Question 1 and Question 2 to identify additional potential  
1119 mitigations needed.
- 1120 • Expand the mitigations to cover additional threats identified (including those from  
1121 additional attack trees created) and controls prioritized by the CSF Profile Subcategories.
- 1122 • Develop a mitigation monitoring plan that incorporates any findings from assessments,  
1123 tabletop exercises, or ongoing monitoring and documents how they will be integrated  
1124 into future threat modeling activities.

1125 The following additional actions help evaluate “Did we do a good job?” answering Question 3,  
1126 “What are we going to do about it?” These activities help evaluate the thoroughness of  
1127 mitigations and regularly consider the impact of any changes to the system or threat  
1128 environment. A legal review may be appropriate to determine if the mitigations, accepted risks,  
1129 and transferred risks (particularly the manner of transfer notification) meet the necessary  
1130 regulatory requirements (GV.OC-03; MO:1,3,8).

1131 **Review Risk Strategies.** Determine if there is a risk strategy for every threat that crosses a trust  
1132 boundary and consider mitigations and other responses across each risk strategy, such as  
1133 eliminate, accept, and transfer.

- 1134 • **Eliminate.** Eliminating threats often removes features. Whenever threats are  
1135 eliminated, documentation should justify why the risk from a threat was deemed to  
1136 outweigh the benefit from the feature. This documentation is necessary because threat  
1137 models will need to be revisited as the system and organization evolves. Future threat  
1138 modeling efforts may involve different participants who may not be familiar with the  
1139 system and will rely on documentation.

- 1140 • **Accept.** Threats that are risk-accepted should be documented sufficiently to explain why  
1141 the risk was accepted. For example, an authentication threat may be accepted because  
1142 there is no remote login and there are physical controls restricting access to a device.  
1143 The reason for the risk acceptance needs to be documented so that if the system is  
1144 modified to allow remote access or moved to a place without physical controls, it will be  
1145 clear that the risk needs to be reassessed.

- 1146 • **Transfer.** When threats are transferred, complete and sufficient documentation fully  
1147 assigns responsibility to the entity assuming accountability for the risks that derive from  
1148 that threat. That entity may then also be responsible for accepting, mitigating, or  
1149 transferring the risk. For example, responsibility for authorizing and authenticating  
1150 Research Partner users who can access the Genomic Sequencing Laboratory data could  
1151 be transferred to the Research Partner. Does the documentation adequately inform the  
1152 Research Partner of their responsibility and define what the required authentication  
1153 mechanism is (such as username and password or MFA)?

1154 **Update DFDs.** As mitigations are added, DFDs may need to be updated. Threats against that  
1155 element should be considered, and a risk strategy should be assigned to eliminate, mitigate,  
1156 accept, or transfer. For example, if you add a firewall, the DFD should be updated to include the



1157 firewall (a firewall may have an administration console, a configuration file, etc.) and then  
1158 evaluate the threats against the firewall.

1159 **Review Attack Trees.** Attack trees are a helpful tool in addressing the question, “Did we do a  
1160 good job?” particularly when they are based on methods or TTPs that have been known to be in  
1161 use by adversaries. If there are mitigations in place that sever the attack tree in multiple places,  
1162 that can be a positive indication of the layering of controls which can be part of a robust  
1163 cybersecurity defense.

1164 **Use CSF Profiles.** Teams can use the *Genomic Data Profile* to identify additional mitigations by  
1165 considering priority Subcategories for each Mission Objective. The mitigations selected during  
1166 Question 3 activities can be mapped to CSF Subcategories and used to develop a CSF Profile  
1167 tailored to the organization. The organization can identify potential gaps by comparing the  
1168 organization’s CSF Profile to an appropriate target profile like those provided by the *Genomic*  
1169 *Data Profile* [\[4\]](#).

1170 **Track Mitigations Throughout the System Lifecycle.** Threat mitigations should be documented,  
1171 reviewed, tested, and maintained as the threat environment changes. This may include the  
1172 following considerations:

- 1173 • During the implementation phase, the threat modeling should be periodically revisited  
1174 and updated. Consider whether the mitigations caused problems and if so, what were  
1175 the impacts.
- 1176 • Once mitigations are operational, consider their effectiveness and any negative impact  
1177 to Mission Objectives. During security incident response and recovery, determine if  
1178 mitigations increase or decrease system uptime (ID.IM-03; MO:1,3,8). If the mitigation  
1179 decreased system uptime, consider if the protection provided by the mitigation justified  
1180 the loss of system availability.
- 1181 • Organizations should update their threat model after a device or mitigation fails. While  
1182 device failures are often unrelated to cybersecurity issues, they can be useful for  
1183 evaluating resiliency measures, which are an important part of response and recovery  
1184 from cyber incidents.
- 1185 • Organizations should update their threat model when any significant modifications are  
1186 made to the system.
- 1187 • Security assessment, including automated and manual penetration testing, is another  
1188 useful tool to evaluate how the mitigations and threat modeling perform and how they  
1189 can be improved.
- 1190 • Tabletop and Functional Exercises as described in NIST Special Publication (SP) 800-84  
1191 [\[23\]](#) can also be very helpful in evaluating Question 3 of the threat modeling process  
1192 and can be done both before and after a system is in use (ID.IM-02; MO:1,3,8).

### 1193 3. Conclusion

1194 This paper demonstrates cybersecurity threat modeling techniques to evaluate potential  
1195 threats for the common genomic data processing use case where:

- 1196 • An organization (Research Partner) sends a physical DNA sample and associated  
1197 metadata (in digital form) to a genomic sequencing provider (Genomic Sequencing  
1198 Laboratory).
- 1199 • The Genomic Sequencing Laboratory generates genomic data from the physical sample,  
1200 processes the data, and sends the results to the Research Partner.
- 1201 • The Research Partner then analyses the data using tools that include untrusted software  
1202 and publicly available reference data.

1203 This paper provides an example of how a threat modeling process can be employed in a  
1204 systematic and consistent manner to analyze threats to the Research Partner and Genomic  
1205 Sequencing Laboratory environments. It shows how the process identifies dataflows in each  
1206 environment and highlights the high-value dataflows that may warrant additional mitigations. It  
1207 also identifies and characterizes some key threats against these environments and describes  
1208 sample mitigations genomic data processing organizations may consider.

1209 This threat modeling process identified three areas where genomic data processing concerns  
1210 and threats differed from most enterprise applications:

- 1211 • Protections to address the unique value and potential size of genomic data, including  
1212 closely managing remote access when sharing with external partners
- 1213 • Controls to protect the data when running untrusted researcher code during genomic  
1214 data analysis
- 1215 • Safeguards to protect the highly valuable sequencers in the internal network that  
1216 process sensitive genomic data and provide manufacturers access for maintenance

1217 Organizations that process genomic data can use this paper to guide them in conducting threat  
1218 modeling on their own unique environments. The threat model results can be used to:

- 1219 • Guide system development and implementation choices to mitigate threats to the  
1220 organization.
- 1221 • Document how a system is intended to function, threats to the system, and strategies to  
1222 address those threats.
- 1223 • Assess the cyber threats against a current system as an input to the risk assessment  
1224 process.
- 1225 • Develop their own CSF Organizational Profile that tailors the NCCoE-published *Genomic  
1226 Data Profile* to identify and prioritize threat-informed mitigations.
- 1227 • Assess the threat reduction value to the organization of proposed new mitigations.
- 1228 • Evaluate the risk to a system of a cyber incident or vulnerability that the organization  
1229 may be concerned about due to recent news events or threat intelligence.

- 1230       • Assess proposed enhancements to the current system functionality for additional  
1231        threats that should be considered because of the proposed changes.
- 1232       While this paper focuses on cybersecurity threats, the NCCoE is developing a privacy-focused  
1233       guide to address privacy-related concerns, threats, and risks that will also be published.

1234 **References**

- 1235 [1] Genetic Information Nondiscrimination Act of 2008, Pub. L. 110-233, 122 Stat. 811.  
1236 <https://www.govinfo.gov/app/details/PLAW-110publ233>
- 1237 [2] Executive Order 14081 (2022) Advancing Biotechnology and Biomanufacturing  
1238 Innovation for a Sustainable, Safe, and Secure American Bioeconomy. (The White House,  
1239 Washington, D.C.), DCP-202200786, September 12, 2022.  
1240 <https://www.govinfo.gov/content/pkg/FR-2023-04-27/pdf/2023-08841.pdf>
- 1241 [3] Pulivarti R, Martin N, Byers F, Wagner J, Maragh S, Wilson K, Wojtyniak M, Kreider B,  
1242 Frances A, Edwards S, Morris T, Sheldon J, Ross S, Whitlow P (2023) Cybersecurity of  
1243 Genomic Data. (National Institute of Standards and Technology, Gaithersburg, MD), NIST  
1244 Interagency or Internal Report (IR) NIST IR 8432. <https://doi.org/10.6028//NIST.IR.8432>
- 1245 [4] Martin N, et al. (2023) Cybersecurity Framework Profile for Genomic Data. (National  
1246 Institute of Standards and Technology, Gaithersburg, MD), Initial Public Draft NIST  
1247 Interagency or Internal Report (IR) 8467. <https://doi.org/10.6028/NIST.IR.8467.ipd>
- 1248 [5] National Institute of Standards and Technology (2006) Minimum Security Requirements  
1249 for Federal Information and Information Systems. (Department of Commerce,  
1250 Washington, D.C.), Federal Information Processing Standards Publications (FIPS PUBS)  
1251 200. <https://doi.org/10.6028/NIST.FIPS.200>
- 1252 [6] Dodson DF, Montgomery DC, Polk WT, Ranganathan M, Souppaya MP, Johnson S, Kadam  
1253 A, Pratt C, Thakore D, Walker M, Lear E, Weis B, Barker WC, Coclin D, Hojjati A, Wilson C,  
1254 Jones T, Baykal A, Cohen D, Yeich K, Fashina Y, Grayeli P, Harrington J, Klosterman J,  
1255 Mulugeta B, Symington S, Singh J (2021) Securing Small-Business and Home Internet of  
1256 Things (IoT) Devices: Mitigating Network-Based Attacks Using Manufacturer Usage  
1257 Description (MUD). (National Institute of Standards and Technology, Gaithersburg, MD),  
1258 NIST Special Publication (SP) 1800-15. <https://doi.org/10.6028/NIST.SP.1800-15>
- 1259 [7] Dempsey KL, Chawla NS, Johnson LA, Johnston R, Jones AC, Orebaugh AD, Scholl MA,  
1260 Stine KM (2011) Information Security Continuous Monitoring (ISCM) for Federal  
1261 Information Systems and Organizations. (National Institute of Standards and Technology,  
1262 Gaithersburg, MD), NIST Special Publication (SP) 800-137.  
1263 <https://doi.org/10.6028/NIST.SP.800-137>
- 1264 [8] U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health  
1265 (CDRH) (2023) Cybersecurity in Medical Devices: Quality System Considerations and  
1266 Content of Premarket Submissions. Available at [https://www.fda.gov/regulatory-  
1267 information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-  
1268 system-considerations-and-content-premarket-submissions](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cybersecurity-medical-devices-quality-system-considerations-and-content-premarket-submissions)
- 1269 [9] The MITRE Corporation and Medical Device Innovation Consortium (MDIC) (2021)  
1270 Playbook for Threat Modeling Medical Devices. Available at  
1271 [https://www.mitre.org/sites/default/files/2021-11/Playbook-for-Threat-Modeling-  
1272 Medical-Devices.pdf](https://www.mitre.org/sites/default/files/2021-11/Playbook-for-Threat-Modeling-Medical-Devices.pdf)
- 1273 [10] Threat Modeling Manifesto Working Group (2021) The Threat Modeling Manifesto.  
1274 Available at <https://www.threatmodelingmanifesto.org/>

- 1275 [11] Shostack A (2014) Threat Modeling: Designing for Security (Wiley, Hoboken, NJ) 1<sup>st</sup> Ed.  
1276 [https://www.wiley.com/en-us/Threat+Modeling%3A+Designing+Security-p-](https://www.wiley.com/en-us/Threat+Modeling%3A+Designing+Security-p-9781118809990)  
1277 [9781118809990](https://www.wiley.com/en-us/Threat+Modeling%3A+Designing+Security-p-9781118809990)
- 1278 [12] Cooper DA, Apon D, Dang QH, Davidson MS, Dworkin MJ, Miller CA (2020)  
1279 Recommendation for Stateful Hash-Based Signature Schemes. (National Institute of  
1280 Standards and Technology, Gaithersburg, MD), NIST Special Publication (SP) 800-208.  
1281 <https://doi.org/10.6028/NIST.SP.800-208>
- 1282 [13] U.S. Food and Drug Administration (FDA) (2024) Medical Device Product Classification of  
1283 High Throughput DNA Sequence Analyzer. Available at  
1284 <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm?ID=PFF>
- 1285 [14] Saadia A, et al. (2021) Analysis of security and privacy challenges for DNA-genomics  
1286 applications and databases. *Journal of Biomedical* 119(103815).  
1287 <https://doi.org/10.1016/j.jbi.2021.103815>
- 1288 [15] Ney P, et al. (2017) Computer Security, Privacy, and DNA Sequencing: Compromising  
1289 Computers with Synthesized DNA, Privacy Leaks, and More. *2017 USENIX Security*  
1290 Symposium, (University of Washington, Seattle, WA) pp. 1-15.  
1291 <https://dnasec.cs.washington.edu/dna-sequencing-security/dnasec.pdf>
- 1292 [16] Chard K, et al. (2018) The Modern Research Data Portal: a design pattern for networks,  
1293 data-intensive science. *PeerJ Computer Science* 4:e144. [https://doi.org/10.7717/peerj-](https://doi.org/10.7717/peerj-cs.144)  
1294 [cs.144](https://doi.org/10.7717/peerj-cs.144)
- 1295 [17] Chandramouli R (2022) Guide to a Secure Enterprise Network Landscape. (National  
1296 Institute of Standards and Technology, Gaithersburg, MD), NIST Special Publication (SP)  
1297 800-215. <https://doi.org/10.6028/NIST.SP.800-215>
- 1298 [18] National Security Agency (NSA) and Cybersecurity Infrastructure & Infrastructure Security  
1299 Agency (CISA) (2021) Selecting a Protective DNS Service, Ver. 1.2. Available at  
1300 [https://media.defense.gov/2021/Mar/03/2002593055/-1/-](https://media.defense.gov/2021/Mar/03/2002593055/-1/-1/0/CSI_PROTECTIVE%DNS_UOO117652-21.PDF)  
1301 [1/0/CSI\\_PROTECTIVE%DNS\\_UOO117652-21.PDF](https://media.defense.gov/2021/Mar/03/2002593055/-1/-1/0/CSI_PROTECTIVE%DNS_UOO117652-21.PDF)
- 1302 [19] PacBio (2024) Revio™ system: Site preparation guide. Available at  
1303 <https://www.pacb.com/wp-content/uploads/Guide-Revio-system-site-preparation.pdf>.
- 1304 [20] PacBio (2024) Featured Documentation. Available at  
1305 <https://www.pacb.com/support/documentation/>
- 1306 [21] OpenSSL enc - symmetric cipher routines. Available at  
1307 <https://docs.openssl.org/1.1.1/man1/enc/>
- 1308 [22] Quobyte (2024) Quobyte. Available at <https://www.quobyte.com>
- 1309 [23] Grace T, Nolan T, Burke K, Dudley R, White G, Good T (2006) Guide to Test, Training, and  
1310 Exercise Programs for IT Plans and Capabilities. (National Institute of Standards and  
1311 Technology, Gaithersburg, MD), NIST Special Publication (SP) 800-84.  
1312 <https://doi.org/10.6028/NIST.SP.800-84>

1313 **Appendix A. Abbreviations and Acronyms**

1314 The following acronyms are used in this publication.

1315 **ACL**

1316 Access Control List

1317 **API**

1318 Application Programming Interface

1319 **AWS**

1320 Amazon Web Services

1321 **BAM**

1322 Binary Alignment Map

1323 **CRAM**

1324 Compressed Reference-oriented Alignment Map

1325 **CRISPR**

1326 Clustered Regularly Interspaced Short Palindromic Repeats

1327 **CSF**

1328 NIST Cybersecurity Framework

1329 **DFD**

1330 Data Flow Diagram

1331 **DISA**

1332 Defense Information Systems Agency

1333 **DMZ**

1334 Demilitarized Zone

1335 **DNA**

1336 Deoxyribonucleic acid

1337 **DNS**

1338 Domain Name System

1339 **DoS**

1340 Denial of Service

1341 **EDL**

1342 External Dynamic List

1343 **EoP**

1344 Elevation of Privilege

1345 **FDA**

1346 U.S. Food and Drug Administration

1347 **GB**

1348 Gigabytes

1349 **HTTPS**

1350 Hypertext Transfer Protocol Secure

1351	<b>HVD</b>
1352	High Value Dataflow
1353	<b>ICS</b>
1354	Industrial Control Systems
1355	<b>ID</b>
1356	Identifier
1357	<b>IP</b>
1358	Internet Protocol
1359	<b>IT</b>
1360	Information Technology
1361	<b>LDAP</b>
1362	Lightweight Directory Access Protocol
1363	<b>LIMS</b>
1364	Laboratory Information Management System
1365	<b>MDIC</b>
1366	Medical Device Innovation Consortium
1367	<b>MFA</b>
1368	Multifactor Authentication
1369	<b>MO</b>
1370	Mission Objective
1371	<b>NCBI</b>
1372	National Center for Biotechnology Information
1373	<b>NCCoE</b>
1374	National Cybersecurity Center of Excellence
1375	<b>NFS</b>
1376	Network File System
1377	<b>NIH</b>
1378	National Institutes of Health
1379	<b>NIST</b>
1380	National Institute of Standards and Technology
1381	<b>NTP</b>
1382	Network Time Protocol
1383	<b>OS</b>
1384	Operating System
1385	<b>OSS</b>
1386	Open-Source Software
1387	<b>PaaS</b>
1388	Platform as a Service

1389	<b>Playbook</b>
1390	<i>Playbook for Threat Modeling Medical Devices</i> (MITRE and Medical Device Innovation Consortium, 2021)
1391	<b>QC</b>
1392	Quality Control
1393	<b>RBAC</b>
1394	Role-Based Access Control
1395	<b>REST</b>
1396	Representational State Transfer
1397	<b>RNA</b>
1398	Ribonucleic Acid
1399	<b>SaaS</b>
1400	Software as a Service
1401	<b>SMB</b>
1402	Server Message Block
1403	<b>SP</b>
1404	NIST Special Publication
1405	<b>SSDF</b>
1406	Secure Software Development Framework
1407	<b>SSO</b>
1408	Single Sign-On
1409	<b>STIGs</b>
1410	Security Technical Implementation Guides
1411	<b>STRIDE</b>
1412	Spoofing, Tampering, Repudiation, Information Disclosure, and Elevation of Privilege threat analysis
1413	<b>TCP</b>
1414	Transmission Control Protocol
1415	<b>TLS</b>
1416	Transport Layer Security
1417	<b>TTPs</b>
1418	Tactics, Techniques, and Procedures
1419	<b>UI</b>
1420	User Interface
1421	<b>VM</b>
1422	Virtual Machine
1423	<b>VPN</b>
1424	Virtual Private Network